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SUMMARY 
This thesis aims to examine three key questions: 
1. Can digital finger pressure measurements and the derivative digital brachial 
pressure index help to identify patients at risk of arteriovenous access ischaemic 
steal? 
2. Is it possible to reduce reported rates of steal and steal phenomena in autogenous 
fistulae located at the antecubital fossa by modifying the arterial inflow used? 
3. Should elderly patients initiating haemodialysis be consigned to a more proximal 
antecubital fossa (brachial) fistula, or is a more distal wrist (radiocephalic) fistula 
an acceptable alternative? 
 
To address these questions, the vasculature of approximately 500 patients was analysed. 
The work presented in this thesis examines the use of digital finger pressures as a non-
invasive diagnostic modality and underscores the importance of the digital brachial 
pressure index in the determination of steal phenomena and arteriovenous access 
ischaemic steal (AVAIS). We identified the incidence of steal phenomena in our cohort, 
which was of a greater scale than anticipated from the existing published literature. In 
Chapter 3, I present the findings for a randomised controlled trial comparing the incidence 
of steal syndrome and steal phenomena for 2 different autogenous fistulae sited at the 
antecubital fossa. Our results demonstrate that patients undergoing haemodialysis via 
antecubital fossa fistula experience a greater incidence of steal phenomena as compared 
to distal fistulae, and that by utilising the proximal radial or ulnar artery as arterial inflow, 
lower rates of steal phenomena are evident.  Finally, Chapter 4 highlights the importance 
of establishing timely autologous vascular access in an elderly incident population. It 
emphasises that this group should not be disadvantaged by the creation of a more 
proximal access which might hasten exhaustion of venous capital.  
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1 INTRODUCTION 
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1.1 An overview of the history of vascular access for 
haemodialysis 
The inception of vascular surgery, vascular access and dialysis therapy are intertwined. 
In 1896, Jaboulay and Briau performed an arterial end-to-end anastomosis in dogs in 
Lyon and subsequently published their technique [1]. A decade later, Alexis Carrel, a 
French surgeon, introduced the three-point end-to-end and side-to-side anastomoses and 
was awarded the 1912 Nobel Prize in Physiology and Medicine in recognition of his work 
on vascular suturing techniques and the transplantation of blood vessels and organs [2].   
 
Dr Willem J. Kolff is credited with developing the first practical artificial kidney in 1943-
1945, using parts from a destroyed German airplane and American sausage casing as his 
semi-permeable membrane [3]. The first horizontal rotating drum artificial kidney 
consisted of a drum built of wooden slats, whereby cellulose tubing holding circulating 
blood was rotated in a 100L porcelain tank containing a “bath” of dialysate, utilising a 
motor from a sewing machine (Figure 1.1; Reproduced from Friedman EA, Olsen DB. 
Memoriam and tribute to Willem J. Kolff, founder of Artificial Organs. ASAIO J 
n.d.;55:181–91. [3]). This development heralded the beginning of renal replacement 
therapy. 
 
Figure 1.1: Replica of Kolff’s 1943 rotating drum artificial kidney 
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Dr Belding H. Scribner introduced the arteriovenous (AV) shunt in 1960, which was an 
external shunt consisting of Teflon tubing bridging an artery and vein (Figure 1.2; 
Reproduced from Bode A et al: Vascular Access for Haemodialysis Therapy, Springer, 
Berlin, Heidelberg; 2013, p. 235–303. [4]). This allowed for dialysis to take place without 
further recannulation or further injections of heparin between dialysis sessions. His first 
patient survived for 11 years after the insertion of his first AV shunt on March 1960. This 
development of a permanent vascular access was a breakthrough, enabling life-
prolonging maintenance dialysis to be feasible. The Scribner shunt was not without 
problems – thrombosis, localised and systemic infections and shunt dislodgment (with 
consequential torrential arterial bleeding) occurred not infrequently [5,6]. While the 
Scribner shunt was ultimately superseded by other forms of vascular access, its 
development heralded the provision of maintenance haemodialysis to the chronic end-
stage renal failure (ESRF) population. 
 
James Cimino and Michael Brescia introduced the autogenous arteriovenous fistula 
(AVF) in 1966 [7] as a means to avoid externalisation of the access site; this was a side-
to-side radiocephalic fistula (Figure 1.3; Reproduced from Brescia MJ et al: Chronic 
Hemodialysis Using Venipuncture and a Surgically Created Arteriovenous Fistula. N 
Engl J Med 1966;275:1089–92. [7]). In total, sixteen patients underwent AVF formation, 
with fourteen achieving primary patency; this is still considered an admirable result by 
modern standards. 
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Figure 1.2: Scribner shunt 
Note the two ends inserted on the left-hand side and the flexible tubing on the left 
functioning as the external shunt, which can then be connected to the extracorporeal 
circuit 
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Figure 1.3: Side-to-side radiocephalic fistula 
Following this ground-breaking publication, there have been multiple variations of 
arteriovenous fistulae. James May (Australia) proposed using a length of saphenous vein 
as an autogenous graft in the elbow, connecting the brachial artery to a suitable vein  [8]. 
A variation of this method was to use the saphenous vein as an autogenous loop graft in 
the thigh.   
 
The synthetic Goretex graft (W.L. Gore & associates, Elkton, MD) was introduced in the 
1970s. Compared to native fistulae, these grafts matured earlier, allowing for quicker 
needle cannulation and thereby gained widespread popularity in the United States. 
However, the Goretex graft is more prone to stenosis, thrombosis and infection. A short 
summary of vascular access milestones is detailed in Figure 1.4.  
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Figure 1.4: Milestones in Vascular Access  
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1.2 End Stage Renal Failure 
1.2.1 Definition 
Chronic kidney disease (CKD) is defined as an abnormality of kidney structure or loss of 
function which is present for more than 3 months, resulting in an estimated glomerular 
filtration rate (eGFR) of <90mL/min/1.73m2, and having an impact on health [9]. It is 
classified into various stages based on eGFR. The terms “end stage renal disease” and 
“CKD stage V” are used interchangeably to describe patients with eGFR of 
<15mL/min/1.73m2, indicating progression towards requiring renal replacement therapy 
[9]. 
 
1.2.2 End Stage Renal Failure in the United Kingdom 
It is estimated that in the United Kingdom over 3 million people suffer from chronic 
kidney disease; of these, more than 58000 Britons receive treatment for end stage renal 
failure (ESRF) [10]. The incidence rate of adult patients initiating renal replacement 
therapy has grown steadily from 103 to 115 per-million-population in the period spanning 
2004 – 2014, representing an increase of 11 percent over ten years  [10,11]. This rate is 
comparable to many other European countries, but lower than in the USA. For patients 
with ESRF, renal replacement therapy offers the only means of life-prolongation [12].   
Although renal transplantation is the gold standard renal replacement therapy, organ 
donor scarcity limits availability; in the UK the median transplant list waiting time is 3 
years [13]. For patients with ESRF, dialysis is therefore usually the first line, and in many 
cases, destination renal replacement therapy. Options include either peritoneal or haemo-
dialysis.  
 
Kidney disease can occur at any age; however, it becomes more common in older age 
groups. Renal glomerular filtration rate is measured, and once it has declined below a 
trigger value, renal replacement is initiated. The average age of initiating renal 
replacement therapy has remained largely unchanged at 64 years. In contrast, the median 
age of a person receiving renal replacement therapy has increased from 55 to 59 years in 
the period spanning 2000-2015 [14]. Earlier identification and intervention following 
progression to renal failure, improved dialysis regimens extending survival times on 
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dialysis, as well as lengthening waiting lists for renal transplantation are all contributing 
factors to patients remaining on dialysis for a longer duration [12,15]. With increasing 
time spent on haemodialysis, maintenance of a functional vascular access remains 
challenging, especially in the context of an aging population with multiple comorbidities. 
For this cohort, repeated interventions and hospital admissions to restore failing vascular 
access are common, resulting in a poor quality of life and substantial healthcare costs 
[16]. Therefore, there is an urgent need to investigate strategies of prolonging venous 
access for the maintenance of haemodialysis; indeed vascular access is often referred to 
as the “Achilles heel” of haemodialysis [6,17].    
 
End stage renal disease has a significant impact on life expectancy as well as quality of 
life. Risk of death at one year for individuals receiving RRT is significantly higher than 
that of the general population and varies according to age group; for patients aged 35-39 
years the risk of death is 22 times higher than the general population and for patients aged 
greater than 85 years this risk is double that of the general population [14]. The need for 
renal replacement therapy also has significant consequences for the individual and their 
families. Major lifestyle modifications are necessary to accommodate treatment, which 
might impact the individual’s ability to earn a living or to attend school or college and 
places a greater burden on family and caregivers. Symptoms such as malaise, fatigue and 
decreased appetite are common [18]. ESRF also places considerable burdens on 
healthcare resources and providers. Approximately 3% of the annual NHS budget is 
utilised to treat 61000 patients with end stage renal failure  [10]. Since 2010, there has 
been an 18% increase in the number of UK patients commencing renal replacement 
therapy [14]. In 2015, a further 7800 new patients started renal replacement therapy in 
the UK. Outpatient haemodialysis costs between £30000 – £35000 per patient annually. 
Similarly, in the United States, a disproportionate percentage (7%) of the total Medicare 
budget is spent on patients with ESRD, which account for less than 1% of the population 
[19].   
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1.3 Current vascular access options 
There are several modalities of providing adequate venous access for haemodialysis – via 
native (autogenous) arteriovenous fistula, synthetic graft, or long-term indwelling central 
venous catheter. Present key guidelines for vascular access include those published by  
the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF-
DOKI) [20], UK Renal Association [21] and, most recently, the European Society for 
Vascular Surgery [22].  These guidelines recommend that arteriovenous fistulae (AVF) 
should be the preferred form of vascular access for long-term haemodialysis in patients 
with end-stage renal failure as they have the lowest risk of complications, lowest rate of 
interventions and best long term patency [17]. Furthermore, mortality is higher amongst 
patients who dialyse via a non-cuffed or cuffed catheter as compared to patients who 
dialyse via either a graft or fistula [23]. Recent data suggests that a single episode of 
catheter-related bacteraemia is associated with an increased mortality in the immediate 
post–infection period and for the following three years [17].  
 
For individuals on long-term haemodialysis, there is a substantial risk of exhausting 
vascular access options following multiple access attempts. Managing a failing vascular 
access site remains a difficult problem. Surgical and percutaneous management of AV 
fistulae and grafts, as well as stents and stent grafts have been suggested as possible 
methods to treat access complications. Treatment of central venous stenosis and 
occlusions from repeated CVC insertion or prolonged usage remain challenging issues. 
 
1.3.1 Arteriovenous fistulae 
Autogenous arteriovenous fistulae (AVF) are the preferred modality for haemodialysis 
provision as there is a lower incidence of associated morbidity and mortality as compared 
to other access modalities. An AVF is created by surgically connecting a low flow, low 
resistance venous outflow to a high flow, high resistance arterial inflow. This fistula is 
then allowed to develop over 4-8 weeks [24] to allow for arterialisation of the venous 
component to take place which renders it sufficiently durable to be needled repeatedly. 
This process is termed “maturation”. During this interval, haemodynamic changes such 
as increased cardiac contractility, increased stroke volume, increased cardiac output, 
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reduced systemic vascular resistance and left ventricular dilatation or hypertrophy take 
place [25,26]. 
 
Current UK Renal Association guidelines recommend that AVF placement should be 
initiated at least 6 months prior to planned commencement of haemodialysis [21]. This is 
to ensure an adequate timeframe to allow for fistula maturation; this may involve salvage 
procedures to aid maturation or, should there be primary failure of the initial fistula, 
alternative fistula placement. Distal (radiocephalic) fistulae are often created in the first 
instance to preserve precious venous capital for subsequent proximal fistulae. In reality, 
there is wide institutional variation from time of referral to actual fistula creation, with 
early fistula formation resulting in a greater number of functioning autogenous AVFs, 
while delayed creation increases the risks of fistula non-maturation and consequent CVC 
utilisation [27–29].   
 
There are various types of arteriovenous fistulae (AVF) and numerous ways of describing 
them (Table 1.1). In 2002, the Society of Vascular Surgery published recommended 
standards for reporting access outcomes [30], and the vascular access community has 
largely adopted these conventions in further reporting. Arterial inflow is reported first, 
followed by the venous outflow. Other descriptors such as “transposed”, “translocated”, 
“straight” or “looped” may sometimes be used as well. These conventions are used 
throughout this thesis. 
 
There is considerable worldwide variation in the proportion of patients initiating 
haemodialysis via arteriovenous fistula, with the highest incidence and prevalence rates 
of 80% in Europe and Japan, and the lowest levels in the USA [31]. To mitigate this, in 
2004, the “Fistula First Initiative” was introduced in the USA, which advocated the 
placement of AVFs in all suitable haemodialysis patients. This breakthrough initiative 
sought to improve healthcare outcomes for haemodialysis patients whilst reducing costs 
for the Medicare programme. 
 
Chapter 1: Introduction 
   11 
The “Fistula First” initiative is based on a multidisciplinary team consisting of 
nephrologists, renal access nurses and surgeons. Its goals are:  
 Early identification and referral to nephrologists 
 Subsequent referral to surgeons for “AVF only” 
 Fashioning AVF in appropriate patients with existing AVG or CVC 
 Cannulation training 
 Patient and staff education 
 Monitoring and surveillance, with recognition of failing access 
 Continuous quality improvement review 
Since the commencement of this initiative, there has been a rapid rise in the AVF 
prevalence rate in the USA from 24% in 1999 to just over 60% in 2012 [32].  
 
Similarly, in the United Kingdom, current Renal Association guidelines advocate that a 
native arteriovenous fistula should be the vascular access modality of choice, given 
comparative reduced hospitalisation frequency and overall costs [21]. Within the UK, 
there remains wide geographical variation in local processes and service delivery, such 
as time to referral for access assessment, local access preference and the presence of 
dedicated operating lists for vascular access creation [10]. This has had a direct impact in 
the prevalence of vascular access modalities. What is still yet to be addressed is that fistula 
placement often follows CVC line insertion, which is still the access modality favoured 
for “crash landers” – patients who require immediate renal replacement upon 
presentation. 
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Type of access 
Upper Extremity 
Snuffbox [33] 
Radiocephalic 
Radiobasilic (transposed) 
Ulnabasilic 
Brachiocephalic 
Brachiobasilic (single / two – stage) 
Lower Extremity 
Saphenopopliteal  
Saphenofemoral loop  
End-to side superficial femoral vein to artery upper thigh superficial femoral 
vein transposition loop  [34] 
Dorsalis pedis – long saphenous [35] 
Posterior tibial – long saphenous 
 
Table 1.1 : Types of autogenous arteriovenous fistulae 
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1.3.1.1 Determining AVF maturity 
At present, there is no uniform definition as to what constitutes a “mature fistula”. No 
studies have specified and validated criteria to determine when a fistula is ready for 
cannulation [36].  Routine preoperative vessel mapping does not appear to improve fistula 
maturation rates [37–39]. Some studies have suggested a minimum fistula diameter of 
6mm and suitable fistula wall thickness, without defining the latter quantitatively [40]. 
Guidelines from the National Kidney Foundation Kidney Disease Outcome Quality 
Initiative (NKF KDOQI) have suggested that a fistula is more likely to be usable if they 
meet the “rule of 6s” criteria: flow greater than 600mls/min, diameter of at least 6mm, no 
more than 6 mm deep and discernible margins [20]. However, this is based on expert 
opinion rather than validated studies. Fistula maturation requires a compliant and 
responsive vasculature capable of dilating in response to the increased velocity of blood 
flowing into the newly created low resistance circuit. Successful maturation to a high 
volume flow circuit capable of sustaining haemodialysis typically occurs within the first 
few weeks after creation [41]. 
 
Following AVF creation, it is vital that the fistula be assessed by an experienced member 
of staff between 4-6 weeks after formation. At this point, a decision can be made as to 
whether the fistula is fit for cannulation, whether it should be further assessed in a further 
2-4 weeks to allow for further maturation, or if further intervention (either endovascular 
or surgical) is required. Earlier identification and treatment of a failing fistula is required 
to reduce the time from fistula creation to utilisation and thereby may help to curtail the 
high rate of central venous catheter use for haemodialysis [24].  
 
1.3.1.2 Fistula failure 
Fistula failure can be thought of as an inability of an AVF to provide the requisite blood 
flow to sustain haemodialysis. It can be divided into two broad categories, early and late. 
Early failure comprises of fistulae which following creation were unsuitable for dialysis 
use, whilst late failure encompasses fistulae which were being used for dialysis but 
subsequently failed. Failure subcategories are outlined in Figure 1.5 [42]. 
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Figure 1.5: Fistula failure modalities 
 
Early failure occurs prior to fistula utilisation, and typically arises within 6 weeks 
following fistula creation. Generally, there are 2 categories of early failure – thrombosis 
and non-maturation. Early failure has been attributed to several causes – surgical 
inexperience, poor preoperative vessel selection, usage of borderline vessels and a lack 
of surveillance and maintenance programmes  [43]. 
 
1.3.1.3 Non-maturation 
The term “non-maturation” refers to an AVF that is unsuitable for adequate 
haemodialysis after a minimum of 4 weeks and a maximum of 24 weeks from creation. 
Ever since the initial description of AVF in the 1960s, it has been accepted that 10-30% 
of fistulae will fail to mature. This is the “Achilles heel” of autogenous fistulae. Recently, 
other authors have reported an increase in fistula maturation failure, with a failure to 
mature rate of 24-60% [44–48]. The reasons for this are likely multifactorial: an aging 
population requiring dialysis with a greater burden of disease; better standardised 
reporting according to accepted conventions and a greater drive to create fistulae in 
patients despite suboptimal anatomy. Furthermore, there has been selection bias by some 
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authors reporting access results whereby fistulae experiencing primary failure and 
subsequent abandonment have been omitted from the data analysis, thereby portraying 
overly optimistic patency results. 
 
The classical clinical presentation of a non-maturing AVF is either a thrombosed AVF or 
one that fails to increase in diameter or flow as would be expected. Clinical predictors of 
AVF maturation include size of vessels, site of fistula, surgeon-specific factors, female 
gender, ethnicity, diabetes and peripheral vascular disease [48]. On a practical level, only 
these first three factors are modifiable. 
 
Attempts have been made to develop clinical scoring systems to quantify the risk of 
fistula non-maturation (FTM) to guide the surgeon’s access management strategy. Lok et 
al [48] took into account the following four characteristics: age greater than 65, ethnicity, 
ischaemic heart disease, peripheral vascular disease to produce the following prediction 
score, with each variable scoring 1 if positive:  
3 + 2 × (age ≥ 65) + 3 × (Peripheral vascular disease) +2.5 × (Coronary artery disease) − 
3 × (white) 
The resultant scores range from 0-10.5 and stratifies patients into four risk categories: 
low (<2.0; FTM 24%), moderate (2.0-3.0; FTM 34%), high (3.1-7.9; FTM 50%) and very 
high (>8.0; FTM 69%). Ultimately the aim was to guide decision making for optimal 
access creation, optimising resource allocation while reducing costs associated with 
repeated interventions or further access creation. The basis of Lok’s scoring system was 
a relatively small cohort of 422 patients with fistulae created in a single Canadian 
institution which might solely reflect centre surgical outcomes. In her discussion, she also 
concedes that Afro-Caribbean patients made up less than 10% of the cohort, while other 
ethnicities made up 26% of the cohort; both these populations had higher rates of non-
maturation. While her sample cohort appeared to be heterogenous, further clarity and 
characterisation with regards to ethnicity in the “other ethnicities” group would have been 
instructive. Another criticism is that even for patients deemed to be “low risk”, the 
predicted FTM rate is 24% which seems inordinately high. Subsequent application of this 
scoring system has found limited value in predicting successful AVF use  [44,47].   
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Surgical and endovascular interventions of non-maturing AVFs were examined in a  
systematic review by Voormolen et el, which has shown an overall fistula salvage rate of 
86%, with 1 year primary patency of 51% and 1 year secondary patency of 76% [49]. 
Patients with preoperative clinical or haemodynamic risk factors had increased risk of 
fistula non-maturation (21% and 24%) respectively, but more significantly, individuals 
with low venous flow immediately post-surgery had a significant risk of fistula non-
maturation (50%) [49].    
 
1.3.1.4 Late failure 
The majority of complications causing late fistula failure are a result of access stenosis  
[43]. This can be a consequence of neointimal hyperplasia, needling of the fistula by 
inexperienced dialysis staff or pre-existing proximal stenosis. Unrecognised stenosis 
eventually results in fistula thrombosis. 
 
1.3.1.5 Interventions to salvage a failing fistula 
Whilst both endovascular and surgical modalities are applicable for fistulae in all 
anatomical locations, their application can vary based on available clinical expertise and 
clinical situation. Endovascular techniques include percutaneous transluminal 
angioplasty of the arterial inflow or venous outflow stenoses, dilatation of juxta-
anastomotic stenosis and balloon assisted maturation of non-dilating veins. A recent 
development has been the use of drug eluting balloons to treat stenoses, to reduce the rate 
of neointimal hyperplasia and consequently slow the onset of restenosis, but data remains 
scarce [50–52].  The long term primary assisted patency following percutaneous 
transluminal venoplasty is low [33]. Some authors have reported excellent outcomes 
following aggressive endovascular interventions to dilate stenotic lesions in non-
maturing fistulae [24,53]. These techniques can cause intimal injury, and the resultant 
recurrent intimal hyperplasia and rapid restenosis necessitates multiple reinterventions to 
maintain patency [54]. Other studies, including one systematic review, have suggested 
that surgical revision of a failing fistula  is superior to endovascular intervention [55,56].  
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1.3.2 Arteriovenous grafts 
Arteriovenous grafts (AVGs) provide an intermediate option between AVFs and 
tunnelled catheters, permitting earlier cannulation compared to AVFs. AVGs are utilised 
when a venous limb is unavailable or deemed to be unsuitable for autogenous fistula 
creation, requiring the creation of a prosthetic extra-anatomical vascular access. The 
longevity and patency of AVGs are inferior to that of AVFs, with 1 year primary patency 
rates ranging from 40-60% [57]. Multiple interventions are often necessary to maintain 
access. With aggressive reintervention for graft thrombosis, 1 year secondary patency 
rates of 90% can be achieved [58]. In addition, as the AVG is composed of a synthetic 
material, the risk of infection is higher than that of autogenous fistulae; systemic 
bacteraemia rates of AVGs are 0.5-0.6 per 1000 dialysis days compared to 1.77 per 1000 
dialysis days for CVCs and 0.3 per 1000 dialysis days for an AVF. 
 
Up to 40-50% of incident haemodialysis patients commence dialysis without a functional 
AVF in place [59]. This is a result of a combination of late referral, primary access failure 
and acute presentation of renal failure (so-called “crashlanders”). A limitation of AVF 
deployment is the 6 to 8 week maturation “lag” from creation to first cannulation as well 
as the possibility of early AVF failure, which might necessitate the creation of a new 
autogenous fistula [60]. In contrast, standard AVGs require a delay of approximately 2 
weeks from implantation to initial cannulation, necessitating temporary tunnelled line 
insertion. The recent introduction of early cannulation AVGs, which permit immediate 
needling, may eliminate this delay and consequently avoid the insertion of central venous 
catheters. Some groups have advocated placement of early cannulation grafts as a means 
to avoid central venous catheters, contending that this strategy reduced bacteraemia and 
mortality in patients requiring urgent vascular access [61,62].   
 
1.3.3 Central venous catheters 
Central venous catheters (CVC, Figure 1.6) appear to be the modality of necessity for 
initiation of haemodialysis. Among incident patients in the International Dialysis 
outcomes and Practice Patterns (DOPPS) study, more that 70% of haemodialysis patients 
initiated therapy via CVC [63]. The increased utilisation of central venous catheters 
parallels the growth of patients requiring urgent renal replacement therapy. Several 
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studies have confirmed that patients are more likely to prefer the original dialysis 
modality which is used during initiation of haemodialysis; other studies have confirmed 
that patients who dialyse via CVC are less likely to be amenable to switch to another 
haemodialysis modality, despite a detrimental effect to adjusted mortality [64,65].  
 
Figure 1.6: Double lumen haemodialysis catheter 
 
Dialysis via CVC carries a higher mortality and an increased risk of septicaemia, 
endocarditis and abscess formation [66]. The latest generation of tunnelled haemodialysis 
catheters are larger in diameter when compared to earlier generations, enabling greater 
blood flow rates, but also likely play a role in the development of symptomatic central 
venous stenosis [67].  Repeated CVC insertion or prolonged usage can lead to central 
venous stenosis and obstruction, which are not only challenging to treat but also 
jeopardise future upper limb access [68]. 
 
1.3.4 Complications associated with vascular access creation 
1.3.4.1 Infection 
One of the leading causes of death in adult patients with chronic kidney disease stage 5 
is infection, which can be related to the type of vascular access in use. Rates of infections 
range from 2-3% in native fistulae, 11-35% in arteriovenous grafts and 20-50% in central 
venous catheters [69,70]. 
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Arteriovenous grafts have a greater rate of infection than autogenous fistulae, and often 
requires surgical removal of infected graft material combined with antibiotic therapy for 
complete resolution. Catheter-related sepsis is a serious complication; Saad et al report 
that rates between centres vary from 1.3 to 5.5 episodes per 1000 catheter days [70]. 
 
1.3.4.2 Steal syndrome 
Many complications are associated with AVF/AVG creation, but the most disabling and 
potentially damaging complication is a steal syndrome. Creation of an arteriovenous 
fistula or arteriovenous graft introduces an alternative low resistance pathway for blood 
to flow in preference to the usual high resistance arterial route, resulting in a portion of 
blood being diverted through the AVF/AVG. This non-anatomic shunt results in reduced 
distal arterial flow and consequently impacts distal perfusion. In the literature, multiple 
terms have used to describe this phenomenon: “steal syndrome”, “arteriovenous access 
ischaemic steal (AVAIS)”, “dialysis access steal syndrome (DASS)”, “haemodialysis 
access-induced distal ischaemia (HAIDI)”, “access-related ischaemia”, vascular access 
associated hand ischaemia”, “vascular access induced steal” and “distal hypoperfusion 
ischaemia syndrome”  [71,72].   
 
Present literature suggests that steal syndrome develops in 1 – 10% of patients with an 
AV fistula [73–76]. There is wide variation in the literature in the threshold for reporting 
steal phenomena, making comparisons between studies difficult. Classification of steal 
can be seen in Table 1.2 [75,77]. It can encompass a spectrum of symptoms from cold 
extremities, numbness, hand claudication, to rest pain and tissue loss (Figure 1.7 [71]), 
with intervention unnecessary in the mildest forms, whereas severe steal syndrome is 
debilitating and potentially limb-threatening and mandates surgical revision or ligation of 
the AVF/AVG. Several scoring systems to discriminate the severity of steal syndrome 
have been suggested in previous studies, but none of them have been widely used. Steal 
syndrome can theoretically be assessed with reasonable accuracy by measuring the 
Digital Brachial Pressure Index [78], but again, this approach has not gained widespread 
acceptance. Duplex ultrasound can also be used as a non-invasive modality to evaluate 
the vasculature of the arm and hand and to measure flow velocities, but this requires 
highly-trained vascular scientists. 
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Stage  Symptoms 
0 Asymptomatic 
I Pale/blue and or cold hands without pain (steal phenomenon) 
II Pain on exertion and/or during haemodialysis 
III Rest pain 
IV Tissue loss – ulcers/necrosis/gangrene 
Table 1.2: Classification of Steal syndrome  
 
Pre-existing diabetes, female gender and the position of AVF created are independent 
risk factors for developing steal syndrome [79]. Generally, the more proximal the fistula, 
the greater the risk of steal syndrome. In addition, any patient with arterial occlusive 
disease is potentially at risk. The highest risk is seen in patients with an antecubital AVF 
i.e. brachiocephalic (BCF) or brachiobasilic (BBF) fistulae; up to 50% of patients in some 
studies, compared to 5-8% in all upper limb AVFs [78]. An alternative technique that 
may reduce the risk of developing steal syndrome in the group of patients undergoing 
placement of elbow fistula is to anastomose the vein to the proximal radial artery or ulnar 
artery, just distal to the brachial artery bifurcation. This technique, theoretically, will only 
'steal' blood from one artery; i.e. the radial artery if the anastomosis is created on the 
proximal radial artery, maintaining blood flow through the ulnar arterial system.  
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Recent studies have suggested that using the proximal radial or ulnar artery as inflow 
reduces the risk of developing steal syndrome to as low as 0% to 3% [80–82]. The site of 
arterial inflow of an elbow AFF is therefore a potentially significant factor in causing 
steal syndrome. However, no current randomised controlled trial tests this hypothesis. 
 
 
Figure 1.7: Ulcers on dorsal aspect of little finger secondary to ischaemic steal 
 
A rare but potentially devastating complication of steal is ischaemic monomelic 
neuropathy. This is caused by a reduction of blood flow in the vasa nervorum because of 
steal phenomenon, predominantly in uraemic diabetics with pre-existing neuropathy. 
This results in severe sensorimotor dysfunction of the ulnar, median and radial nerves 
without obvious tissue loss. Symptoms often occur immediately after access creation, and 
if the ischaemia is not immediately reversed, irreversible neurological damage can occur. 
 
Several modalities for the treatment of steal syndrome exist (Figure 1.8; modified from 
the ESVS Vascular Access Clinical Practice Guidelines [22]) . Endovascular treatment 
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of proximal arterial anastomosis can improve the distal arterial flow and consequently 
reduce distal ischemia. Open techniques to reduce the venous outflow include banding, 
plication of the venous segment with sutures, application of metallic clips just distal to 
the anastomosis or interposition of a narrow calibre PTFE graft. However, the degree by 
which the fistula is narrowed can prove to be unpredictable and therefore intra-operative 
digital perfusion by means of pulse oximetry, digital photoplethysmography or duplex 
ultrasound should be undertaken [74,83].  
 
The DRIL (distal revascularisation with interval ligation) procedure can also be 
considered [84–86]. For this technique, the brachial artery just distal to the AV fistula is 
ligated to prevent backflow from the distal artery. A bypass graft from the proximal 
brachial artery to the distal ligated artery is then fashioned. Similarly, the revision using 
distal inflow (RUDI) procedure can be used [74,87–89]. This procedure involves ligating 
the AV anastomosis and revising the arterial inflow  to a more distal source either with 
an interposition graft or by direct anastomosis. Ligation of the AV fistula is also a viable 
treatment, albeit a decision that should be considered as a last resort. 
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Figure 1.8: Surgical techniques for the treatment of steal syndrome 
(A) Flow reduction by banding of the venous component just proximal to the 
anastomosis (B) DRIL procedure (C) RUDI procedure 
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1.3.4.3 Aneurysm formation 
An aneurysm is a localised, pathological dilatation of the wall of a blood vessel. 
Aneurysmal dilatation may develop in an autogenous AVF over the course of many years 
(Figure 1.9). These develop as a result of repeated cannulations and vessel trauma along 
the length of the AVF, resulting in expansion of the autogenous AVF lumen. Needling 
technique also plays a part in aneurysm formation; buttonhole needling is associated with 
lower rates of aneurysm formation as compared to the rope-ladder or area puncture 
techniques [90–92]. Repeated needling results in multiple fibrotic scars in the vessel wall, 
which can expand over time leaving localised aneurysmal areas. Similarly, repeated 
localised punctures in prosthetic grafts can result in pseudoaneurysm formation. Whilst 
an aneurysmal AV access may raise concern from dialysis nursing staff, as long as the 
access remains functional for dialysis and the dilatation does not rapidly enlarge, no 
intervention is required. Indications for intervention include compromise of the overlying 
skin or intraluminal thrombus compromising dialysis [76,93]. Treatment of aneurysmal 
AVFs involve either ligation, plication, or creation of an end-to-end anastomosis by 
resecting the redundant aneurysmal segment.  
 
 
 
Figure 1.9: Multiple aneurysms from repeated needling of a right radiocephalic 
fistula 
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1.3.4.4 Central venous stenosis 
Use of central venous catheters can damage the central veins; one study by Kalman et al 
had found that 90% of patients with central vein stenosis had a prior central venous 
catheter insertion [94].  
 
Treatment of central venous stenosis and occlusion (CVSO) is governed by the patient’s 
symptoms. Incidentally detected asymptomatic stenoses should not be treated as these 
lesions can remain quiescent or even regress given time [95]. Conversely, angioplasty of 
such lesions can provoke rapid progression of stenosis. 
 
For symptomatic patients, management is governed by several factors including 
symptoms severity, aetiology of CVSO and presence of an ipsilateral vascular access 
(Figure 1.10 and Figure 1.11 [96]). Haemodialysis patients with CVSO often present with 
a high-grade stenosis or functional occlusion, but without significant amounts of 
intraluminal thrombus (Figure 1.12  [96]). Angioplasty is often used, however recurrent 
stenosis is likely and therefore close clinical surveillance and repeated intervention are a 
mainstay of treatment [97–99]. 
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Figure 1.10: Left ulnar-basilic fistula causing significant left arm lymphoedema 
Also note the right infraclavicular pacemaker which would contribute to central 
venous stenosis as demonstrated by the prominent veins on the anterior chest wall 
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Figure 1.11: Post ligation of left ulnar basilic fistula 
The picture demonstrates resolution of the left arm lymphoedema secondary to a 
arteriovenous fistula and central vein stenosis. Note that the patient was dialysing 
via an axillo-iliac graft 
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Figure 1.12: Venogram of the patient in Figure 1.10 demonstrating (A) Stenosis of 
the right subclavian vein (B) Occluded left brachiocephalic vein with distal 
collateralisation  
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1.3.4.5 High output cardiac failure 
High output cardiac failure secondary to arteriovenous fistula formation, whilst 
exceedingly rare, is a well described phenomenon [76,100–102]. In contrast, its presence 
in relation to placement of a prosthetic graft is a less recognised phenomenon with limited 
reports [96,103]. Essentially, there is a marked reduction in systemic vascular resistance 
secondary to the functional vascular access, resulting in hypotension and fluid overload. 
Previous studies have shown that a vascular access flow/cardiac output (Qa/CO) ratio in 
excess of 30% place patients at risk of developing cardiac failure [102]. For individuals 
with autogenous fistulae, cardiac failure occurs insidiously. In contrast, for patients with 
prosthetic grafts, typically there is rapid onset of symptoms following insertion of the 
graft. With the advent of the Fistula First Initiative, elderly patients requiring prosthetic 
grafts tend to be cardiovascularly poor and with multiple previous attempts at autogenous 
fistula formation. Therefore, it is conceivable that a modest Qa from a graft could still 
precipitate catastrophic cardiac failure. 
 
To mitigate the above risks, patients with pre-existing cardiac comorbidities should have 
preoperative echocardiograms and other investigations to determine their cardiac reserve. 
This may identify patients at high risk for development of cardiac failure and may even 
influence the decision to proceed with graft placement. It is important to consider the 
hemodynamic consequences when utilising central vessels for vascular access, 
particularly in the presence of underlying cardiac and vascular disease. In especially frail 
patients a tunnelled line might be the only option for vascular access.  
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1.4 Definition of Variables 
Unless otherwise specified, all vascular access definitions were in accordance with the 
Society of Vascular Surgery/American Association of Vascular Surgery and North 
American Vascular Access Consortium [30,36]. Thus: immediate vascular access failure 
refers to an access that has a loss of bruit or thrill within 72 hours of creation; primary 
patency is defined as the interval from time of initial fistula placement until any 
intervention is performed to maintain or re-establish patency; and secondary patency is 
defined as the time of access placement until access abandonment. Proximal revision of 
a radiocephalic fistula that had failed immediately was considered as formation of a new 
primary fistula; proximal revision of a radiocephalic fistula in other circumstances was 
categorized as maintenance of secondary patency. Revascularisation using distal inflow 
(RUDI) procedure [77,88,89]; performed to ameliorate steal syndrome following creation 
of an antecubital fistula; was also considered as  an intervention to maintain secondary 
patency.  
 
To characterise the various grades of steal the grading system proposed by Padberg et el 
was used and this is detailed in Section 1.3.4.2 and Table 1.2 [76]. As mentioned above, 
there is no consensus in reporting standards for steal syndrome in the current literature, 
making comparisons between studies difficult. 
 
A fistula was deemed matured if it sustained dialysis for at least three consecutive 
sessions [104]. This was based on previous published work in our unit and has been 
maintained throughout this thesis for consistency. A common accepted definition for a 
matured fistula is one that sustains six consecutive episodes of dialysis. 
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1.5 Scope of the thesis 
As dialysis access procedures become increasingly complex, identification and 
management of complications have become a significant challenge. Current gaps in the 
literature include:  
1. The relationship between brachial, pre- and post-operative digital pressure and  
the derivative digital brachial pressure index (DBPI) and symptomatic steal 
2. The relationship between fistula flow rate and steal severity 
3. The incidence of steal phenomena and steal syndrome in patients with antecubital 
fossa fistulae is uncertain and not clearly characterised in the literature 
4. It is also unclear if utilising a distal arterial inflow (proximal radial/ulnar artery) 
in the antecubital fossa can improve reported symptoms of arteriovenous access 
associated steal compared to conventional fistulae utilising the brachial artery 
5. The optimal autogenous access modality for elderly patients given their presumed 
limited life expectancy 
 
For the purpose of this thesis, the vasculature of approximately 500 patients was analysed. 
This thesis aims to examine three key questions: 
1. Can digital finger pressure measurements and the derivative digital brachial 
pressure index help to identify patients at risk of arteriovenous access ischaemic 
steal? 
2. Is it possible to reduce reported rates of steal and steal phenomena in autogenous 
fistulae located at the antecubital fossa by modifying the arterial inflow used?  
3. Should elderly patients initiating haemodialysis be consigned to a more proximal 
antecubital fossa (brachial) fistula, or is a more distal wrist (radiocephalic) fistula 
an acceptable alternative? 
 
These questions attempt to address the aforementioned gaps outlined above. Each 
question is examined, in turn, by the chapters following. All research was conducted at 
Cambridge University NHS Foundation Trust. Addenbrookes Hospital served as the 
primary base, and arteriovenous fistulae were created by two experienced consultant 
transplant surgeons and a team of senior trainees under consultant supervision. 
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Recruitment of patients to address the second question proved to be challenging and is 
discussed further in Chapter 3. Upon reflection, this was due to the success of our unit’s 
radiocephalic fistula programme which naturally led to the third question – if 
radiocephalic fistulae should be offered to elderly patients with supposed limited life 
expectancy and this is addressed in Chapter 4.  
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2 THE ROLE OF DIGITAL 
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DIGITAL BRACHIAL 
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ISCHAEMIC STEAL (AVAIS) 
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2.1 Introduction 
Haemodialysis (HD) via arteriovenous fistula (AVF) is the best modality for renal 
replacement therapy [20]. When compared to central venous dialysis catheters or 
arteriovenous grafts, AVFs have longer patency rates and have a reduced incidence of 
infection, stenosis and thrombosis [20]. As a consequence, mortality rates for patients 
dialysing via an AVF are lower compared to other dialysis modalities [105]; current 
guidelines advocate a “fistula first” approach in the provision of vascular access [20,106].  
 
Arteriovenous fistulae are however not without drawbacks. One of the recognised 
complications of having an upper limb AVF is hand ischaemia which affects between 1-
10% of patients [73–76].  This occurs as a consequence of preferential flow into the high 
flow, low resistance venous anastomosis at the expense of distal arterial circulation, 
resulting in hypoperfusion distal to the anastomosis. In theory, all patients with an AVF 
will have some degree of distal vascular compromise, albeit in the majority this 
compromise does not manifest clinically. In the remainder, distal hypoperfusion results 
in a constellation of symptoms, which, ranging from mild to more severe, include cold 
hands, paraesthesia, digital claudication, rest pain and gangrene (Figure 2.1).  At its most 
severe, urgent surgical intervention is required. Individuals more likely to develop 
symptomatic arteriovenous access ischaemic steal (AVAIS) include those of female 
gender, diabetes mellitus, and age greater than 60 [73]. Furthermore, the incidence of 
AVAIS for patients with brachiocephalic fistulae is 5-10 fold greater than that of patients 
with radiocephalic fistulae [73–75,107]. 
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Figure 2.1: Complications of ischaemic steal  
(A) digital cyanosis (B) tissue loss over proximal interphalangeal joints and 
ischaemic nail changes 
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Attempts have been made to grade AVAIS to facilitate comparison of severity, to aid in 
defining the necessity of various treatment options and allow evaluation of treatment 
efficacy following radiological or surgical interventions [77]. Scheltinga et al [71], 
refining work published by Tordoir [75], proposed grading ischaemic steal syndrome 
based on clinical symptoms, but this is not closely correlated with any objective 
measurements (Table 1.2). This closely mirrors the Fontaine score used to grade chronic 
lower limb ischaemia [108,109]. Van Hoek et al [110] used a patient orientated score, by 
means of a comprehensive visual analog scale to rate the severity and frequency of each 
of the five AVAIS symptoms i.e. coldness, paraesthesia, pain, weakness and cramps in 
the fistula hand.  
 
Some studies have investigated the role of haemodynamic parameters as an objective tool 
to assist with the diagnosis of AVAIS and to assess the effectiveness of any intervention 
to ameliorate steal syndrome [78,111,112]. When comparing patients who had revision 
surgery for steal to those without, the Digital brachial pressure index (DBPI) was found 
to be significantly lower in the group of patients with severe steal requiring surgical 
intervention [78,113–115].  However, the role of DBPI in identifying patients with mild 
to moderate steal symptoms remains unclear.  
 
The primary aim of this study was to establish, in HD patients with mature autogenous 
arteriovenous fistulae, if the digital (finger) pressure of the fistula arm differed 
significantly from that of the contralateral arm and if this had a direct relationship to 
symptoms experienced. The secondary objective was to investigate the relationship 
between fistula site and resultant digital pressure and DBPI.  
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2.2 Terminology and definitions 
Current published literature uses several terms to describe steal phenomenon. Dialysis 
associated steal syndrome (DASS), haemodialysis access induced distal ischaemia 
(HAIDI), access-related ischaemia (ARI), vascular access associated hand ischaemia 
(VAAHI) have been used interchangeably in different publications [72]. A recent 
consensus document has suggested that arteriovenous access ischaemic steal (AVAIS) 
should be the preferred term [72]; to maintain clarity AVAIS is used throughout.  
 
2.3 Methods 
2.3.1 Patients 
A prospective observational study was conducted in the Dialysis Unit at Addenbrooke's 
Hospital, Cambridge, from October 2011 to February 2012. Adult patients on long-term 
haemodialysis for end stage renal failure, dialysing via a functional upper limb 
autogenous arteriovenous fistula were recruited. To be considered functional, fistulae had 
to be used for at least three consecutive haemodialysis sessions [104].  
 
The Addenbrooke's Dialysis Unit accommodates 134 haemodialysis patients. 110 
patients had functional upper limb AV fistulae, of which 107 patients consented to 
participate in the study. A separate 23 patients received renal replacement therapy via 
central venous catheter and one patient dialysed via arteriovenous graft; these patients 
were excluded from the study. One patient had no signs or symptoms of circulatory 
compromise despite having an undetectable digital pressure. This patient was excluded 
from subsequent statistical analyses. 
 
Haemodynamic parameters measured in each patient included brachial (BP) and digital 
(DP) pressures, from which the Digital Brachial Pressure Index (DBPI) was derived.  
Clinical AVAIS was graded using two methods: an Objective Score where examination 
of fistula and non-fistula hands were carried out by the investigator; and the Steal 
Symptom Score reported by dialysis patients using a visual analog scale as previously 
described by Van Hoek et. al [110].  
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2.3.2 Ethical approval 
Ethical approval was granted by the London (East) Research Ethics Committee, REC 
11/LO/1352 {Appendix 7.1 Ethical approval (Chapter 2)}. 
 
2.3.3 Relevant medical history  
Relevant medical history was obtained from the patient and medical notes. History of 
diabetes mellitus, hypertension, ischemic heart disease, cerebrovascular, peripheral 
vascular disease, thromboembolism, smoking history, cause of renal failure, dialysis 
history, the use of anticoagulation therapy, β-blockers, ACE inhibitors, statins, insulin 
and steroids were recorded.  
 
2.3.4 Digital and Brachial pressure  
The systolic digital (DP) and brachial blood pressure (BP) were measured on the fistula 
and contra-lateral arm, and then re-measured on the fistula arm with the fistula manually 
occluded. Digital pressures were measured using a Huntleigh Diagnostics Dopplex 
Assist Range digital pressure machine (Huntleigh Healthcare Ltd, Wales, UK, Figure 
2.2). Brachial pressure was measured using a standard blood pressure cuff. DBPI was 
calculated from the ratio of DP to BP. 
 
Figure 2.2: Huntleigh Dopplex Assist digital pressure machine 
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2.3.5 Objective Score - Clinical Examination of Hand 
Each patient was first assessed clinically to determine if there was a history suggestive of 
either ischaemic claudication or rest pain. Clinical examination included a complete 
upper-limb vascular and neurological assessment. Both fistula and non-fistula sides were 
examined for skin temperature, colour, altered sensation, small muscle wasting, impaired 
motor power, evidence of tissue loss and delayed capillary refill time. 
 
2.3.6 Steal Symptom Score 
All patients completed a questionnaire to score five common symptoms of steal 
syndrome, using a visual analogue scale as detailed in Hoek et al [110]. They were asked 
to rate five domains: the frequency and severity of cold hands, pain, altered sensation 
(numbness/paraesthesia), reduced strength and cramps.  
 
The individual steal symptom score is then calculated using the following formula: 
Frequency of symptom [0 (never) to 10 (always)] x Severity of symptom [0 (no 
complaints) to 10 (maximal complaints)]  
 
Each symptom scores a maximum of 100. The total steal symptom score is the sum of 
the five symptoms scores, giving a maximum score of 500.  
 
2.3.7 Fistula Volume Flow (FVF) 
Fistula volume flow was measured by either Transonic Flow-QC® Monitor (Transonic 
Systems Inc, Ithaca, NY, USA, Figure 2.3) or Doppler on the SonoSite MicroMaxx® 
Ultrasound System (Fujifilm SonoSite Inc, Washington, USA), depending on the 
accessibility of the two appliances at the time of study. The Transonic system measures 
true delivered blood flow through dialysis tubing using “gold standard” transit-time 
ultrasound technology.  
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Using the SonoSite, cross-sectional fistula diameter is first measured on 2D function. 
Doppler is subsequently used to derive the time-averaged mean velocity (TAMV). Fistula 
volume flow is then calculated by multiplying TAMV to fistula diameter. The doppler 
measurement was performed by a single operator using the same transducer to minimise 
operator-dependent error.  
 
 
Figure 2.3: Transonic Flow-QC® Monitor 
2.3.8 Statistical Analysis 
All analyses were performed with GraphPad Prism (v.5.03 GraphPad Software Inc, CA, 
USA) and MedCalc (v 18.10 MedCalc Software, Belgium). Digital pressures and DBPI 
of the fistula arm and contralateral arm were compared using paired t-test. The 
relationship between digital and brachial pressures, DBPI and the steal symptom score 
was evaluated using Pearson’s correlation. The significance of categorical parameters in 
the clinical manifestation of steal syndrome were examined using the Mann-Whitney U 
test.   
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2.4 Results 
2.4.1 Patients 
Demographics, past medical history and cause of renal disease of the 106 dialysis patients 
with functional upper limb fistulae are detailed in Table 2.1. The median age of the study 
population was 76 years old (range 26 to 95 years), and 71.7% (n = 76) were male.  
 
 Haemodialysis cohort (n = 106) 
Age median, years (range) 76 (26-95) 
Gender, male  
 
Comorbidities  
76 (71.7) 
Smoking history 
 
 
27 current smokers (25.5) 
62 ex-smokers (58.5) 
17 non-smokers (16.0) 
Diabetes 54 (50.9%; 6 Type 1 and 48 Type 2)  
Hypertension  81 (76.4) 
Ischaemic heart disease 
 
43 (40.6) 
Aetiology of chronic kidney disease  
 
Idiopathic 
Diabetic nephropathy 
Adult polycystic kidney disease 
Hypertensive nephropathy 
Renovascular disease 
Glomerulonephritis 
Other 
 
 
18 (17.0) 
17 (16.0) 
10 (9.4) 
7 (6.6) 
7 (6.6) 
6 (5.7) 
41 (38.7) 
 
 
Table 2.1: Demographic data 
Categorical variables are presented as number (%)  
Chapter 2: The Role Of Digital Pressure And The Digital Brachial Pressure Index In The Identification Of 
Arteriovenous Access Ischaemic Steal (AVAIS) 
   42 
The cohort was subdivided into 2 groups based on the position of their fistula (forearm 
or antecubital, Table 2.2). 82 patients had fistulae sited in their forearm and 24 had 
antecubital fossa fistulae. Of the 24 patients, seven were felt clinically to be at higher risk 
of steal syndrome at the time of surgery. For these patients, the decision was made to use 
either the proximal radial or ulnar artery just distal to the brachial bifurcation as arterial 
inflow. These seven individuals were excluded from any analyses comparing forearm to 
antecubital fistulae.  
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Type of access Total (n = 106) 
Forearm 82 (77.4%) 
 
(Primary) Radiocephalic 
 
48 
(Primary) Ulnarbasilic 3 
Radiocephalic revision (neoanastomosis) 29 
Ulnarbasilic revision (neoanastomosis) 2 
  
Antecubital fistula 24 (22.6%) 
 
Brachiocephalic 
 
14 
Brachiobasilic 2 
Brachiocephalic revision 1 
Proximal radiocephalic 4 
Proximal ulnarcephalic 2 
Proximal ulnarbasilic 
 
1 
 
Table 2.2: Type of arteriovenous access 
Fistulae in italics were sited in the antecubital fossa but were excluded from analyses 
comparing antecubital fistulae to forearm fistulae. This is due to concomitant blood 
flow in the other artery, which would potentially preserve perfusion to the hand. 
  
Chapter 2: The Role Of Digital Pressure And The Digital Brachial Pressure Index In The Identification Of 
Arteriovenous Access Ischaemic Steal (AVAIS) 
   44 
2.4.2 Digital pressure (DP) 
The digital pressures for the 106 patients can be seen in Figure 2.4. Digital pressures were 
normally distributed; mean DP of the fistula arm was 96mmHg (95% CI 88-104), whilst 
mean DP of the contralateral arm was 137mmHg (95% CI 129-145). The mean difference 
between the digital pressure of the contralateral and fistula arm was 41mmHg ( 95% CI 
35-48).  
 
Of note, digital pressure once the fistula was occluded closely mirrored that of the 
contralateral arm, and both these values closely mirrored that of the brachial pressure 
(Figure 2.4).   
 
Figure 2.4: Scatter diagram of digital pressure (DP), DP when fistula occluded, DP 
of contralateral side and Brachial pressure (BP) 
The red line denotes mean pressure of the cohort  
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There was a strong correlation between the digital pressures of the fistula arm and the 
contralateral side (r = 0.689, Figure 2.5); patients with low contralateral pressures tended 
to have lower digital pressures on the fistula side. This implies that for the majority of 
patients, distal vasculature and perfusion are similar in both arms.  
 
 
Figure 2.5: Correlation of digital pressure on fistula side vs contralateral side 
 
There was also a strong correlation between the digital pressure in the contralateral arm 
and brachial artery pressure (r = 0.689, Pearson’s correlation, Figure 2.6). In contrast, 
correlation between DP on the fistula side and brachial arterial pressure was less strong 
(r = 0.543, Pearson’s correlation, Figure 2.7), reflecting variation in distal perfusion 
caused by the fistula. 
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Figure 2.6: Correlation of contralateral digital pressure vs brachial artery pressure 
There was a strong correlation between contralateral digital pressure and brachial 
artery pressure (r = 0.689, Pearson’s correlation) 
 
Figure 2.7: Correlation between digital pressure on the fistula side and brachial 
arterial pressure 
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2.4.3 Digital Brachial Pressure Index (DBPI) 
The DBPI of all 106 patients is shown in Figure 2.8. DBPI of the fistula arm was 
significantly different from the contralateral arm (P < 0.0001, paired t-test). Similarly, 
DPBI of the fistula arm when the fistula was patent and when it was occluded was also 
significantly different (P < 0.0001, paired t-test). The mean DBPI gain when the fistula 
was occluded was 0.34. As expected, there was no significant difference between the 
DBPI when the fistula was occluded and that of the contralateral arm (P = 0.1862, paired 
t-test). There was also a strong correlation between these values (r = 0.6801, Pearson’s 
correlation). 
 
Figure 2.8: Scatter diagram comparing DBPI of fistula arm vs occluded vs 
contralateral arm 
The red line denotes the mean DBPI of the cohort. * DBPI in the fistula arm was 
significantly different to the contralateral arm (paired t-test, P < 0.0001). ** DBPI 
of the fistula arm was significantly different when the fistula was patent and when 
it was occluded (paired t-test, P < 0.0001). NS, Not significant. 
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2.4.4 Objective Score 
On clinical examination, 30 patients (28.3%) had at least 1 sign of steal syndrome. The 
most common sign detected was a difference in hand temperature between the fistula arm 
and contralateral limb (n = 21, 19.8%). Weakness was present in 11 patients, pallor 
occurred in 7 patients and 5 patients had more severe small muscle wasting in the fistula 
hand than the other hand. Capillary refill time was delayed in 3 patients. Twenty-two 
(20.8%) patients had cooler skin temperature in the fistula hand as compared to the non-
fistula hand.  
 
Using receiver operator characteristic (ROC) analysis (Figure 2.9 and Figure 2.10), the 
predictive ability of digital pressure for a positive clinical examination was estimated by 
calculating the area under the curve (AUC). The AUC was 0.753 (95% CI 0.640-0.868). 
The optimal cut off DP was calculated using Youden’s J statistic (J = Maximum  
{Sensitivity + Specificity -1} ) [116]. The optimal cut off DP was 65mmHg, sensitivity 
was  66.7% (95% CI 47.2-82.7), specificity was 80.3% (95% CI 68.1-87.5), negative 
predictive value was 85.9% (95% CI 78.4 - 91.1). In comparison, at a cut off of 50mmHg, 
the sensitivity was 26.7% (95% CI 12.3-45.9), specificity was 96.1% (95% CI 88.9-99.2) 
and negative predictive value was 76.8% (95% CI 78.4 - 91.1).  
 
Similarly, when the ROC analysis was performed using DBPI instead of DP as a variable, 
the AUC was 0.763 (95% CI 0.661-0.865), and using Youden’s J statistic the optimal cut 
off DBPI was calculated to be 0.57, which yielded a sensitivity of 70% (95% CI 50.6-
85.3), specificity of 76.3% (95% CI 65.2-85.3) and negative predictive value of 86.6% 
(95% CI 78.6 - 91.9). In comparison, at a cut off DBPI of 0.50, the sensitivity was 60.0% 
(95% CI 40.6-77.3), specificity was 81.6% (95% CI 71.0-89.6%) and negative predictive 
value was 81.8% (95% CI 75.2 - 87.0). 
   
Fourteen patients (13.2%) had 2 or more signs of steal syndrome; six patients had more 
than 2 signs of steal syndrome. One patient has critical ischaemia with dry gangrene, rest 
pain and impaired sensation of the index and middle fingers of the fistula hand. 
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Cutoff 
DP Sensitivity% 95% CI Specificity% 95% CI 
Youden's J 
statistic 
< 24.50 0 0.0% to 11.57% 98.68 92.89% to 99.97% -0.013 
< 30.50 6.667 0.8178% to 22.07% 98.68 92.89% to 99.97% 0.053 
< 40.50 16.67 5.642% to 34.72% 98.68 92.89% to 99.97% 0.154 
< 50.00 26.67 12.28% to 45.89% 96.05 88.89% to 99.18% 0.227 
< 61.00 60 40.60% to 77.34% 84.21 74.04% to 91.57% 0.442 
< 65.00 66.67 47.19% to 82.71% 80.26 69.54% to 
88.51% 
0.469 
< 67.50 66.67 47.19% to 82.71% 77.63 66.62% to 86.40% 0.443 
< 70.50 66.67 47.19% to 82.71% 76.32 65.18% to 85.32% 0.430 
< 81.50 70 50.60% to 85.27% 69.74 58.13% to 79.75% 0.397 
< 91.00 76.67 57.72% to 90.07% 52.63 40.84% to 64.21% 0.293 
< 102.0 80 61.43% to 92.29% 50 38.30% to 61.70% 0.300 
< 111.0 80 61.43% to 92.29% 43.42 32.08% to 55.29% 0.234 
< 121.0 86.67 69.28% to 96.24% 32.89 22.54% to 44.63% 0.196 
 
Figure 2.9: ROC curve of digital pressure vs clinical examination 
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Cutoff 
DBPI Sensitivity% 95% CI Specificity% 95% CI 
Youden's J 
statistic 
< 0.2050 3.333 0.08436% to 17.22% 100 95.26% to 100.0% 0.033 
< 0.3000 6.667 0.8178% to 22.07% 97.37 90.81% to 99.68% 0.040 
< 0.4050 30 14.73% to 49.40% 93.42 85.31% to 97.83% 0.234 
< 0.5050 60 40.60% to 77.34% 81.58 71.03% to 89.55% 0.416 
< 0.5250 63.33 43.86% to 80.07% 78.95 68.08% to 87.46% 0.423 
< 0.5550 66.67 47.19% to 82.71% 76.32 65.18% to 85.32% 0.430 
< 0.5650 70 50.60% to 85.27% 76.32 65.18% to 85.32% 0.463 
< 0.5800 70 50.60% to 85.27% 75 63.74% to 84.23% 0.450 
< 0.6000 70 50.60% to 85.27% 73.68 62.32% to 83.13% 0.437 
< 0.7050 73.33 54.11% to 87.72% 60.53 48.65% to 71.56% 0.339 
< 0.8050 86.67 69.28% to 96.24% 47.37 35.79% to 59.16% 0.340 
< 0.9050 93.33 77.93% to 99.18% 32.89 22.54% to 44.63% 0.262 
 
Figure 2.10: ROC curve of DBPI vs clinical examination 
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2.4.5 Steal Symptom Score  
The distribution of reported scores can be seen in Figure 2.11. 30 patients reported no 
change (score = 0) in symptoms as a result of having a fistula. The median score in the 
cohort was 25. Categorical symptom scores are shown in Figure 2.12. The most common 
complaint by patients on the fistula hand was coldness, which accounted for 48.1% of 
patients (n = 51), followed by paraesthesia in 45.3%, cramps in 36.8%, weakness in 
31.1% and pain in 17.9%. Symptoms were mild to moderate in the majority of cases, 
although 17.0% of patients (n = 18) had a total symptom score of more than 100 (Figure 
2.11, median = 25). Coldness, cramps and paraesthesia was also experienced to a lesser 
degree in the non-fistula hands in 27.4%, 25.5% and 22.6% of patients respectively. 
 
11 patients had digital pressures less than 50mmHg; all had a DBPI <0.6. When this group 
was compared against the rest of the cohort with digital pressure greater than 50mmHg, 
there was a significant difference in the Steal symptom score (P = 0.032, Mann-Whitney 
U test).  
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Figure 2.11: Scatter diagram of Steal symptom score distribution. 
Red line denotes mean score. Score range from 0-500. 
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Figure 2.12:Categorical symptom score 
Red line denotes mean score for each variable. Score range from 0-100 
 
Sixteen patients had a contralateral pressure of <100mmHg, with a mean Steal symptom 
score of 96. When these patients’ Steal symptom score was compared against the scores 
from patients with contralateral pressure ≥100mmHg (mean Steal symptom score 45), 
again there was a significant difference in the Steal symptom score (P = 0.011, Mann-
Whitney U test, Figure 2.13). This suggests that patients with low systemic blood 
pressures will tend to have higher Steal symptom scores and will be more symptomatic.  
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Figure 2.13: Comparison of Steal symptom scores for contralateral pressure <100 
and ≥100 mmHg 
 
Nevertheless, there was very poor correlation between the Steal symptom score and 
DP/DBPI, implying that a linear relationship does not exist (r = -0.154 and -0.109 
respectively, Pearson’s correlation, Figure 2.14). 
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Figure 2.14 Correlation between Steal symptom score and fistula side (A) Digital 
pressure (B) DBPI 
There was no linear correlation(A, r = -0.154; B, r = -0.109; Pearson’s correlation). 
r = -0.154 
r = -0.109 
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2.4.6 Fistula Volume Flow  
There was a significant difference in fistula volume flows depending on the site of the 
fistula (P < 0.0001, Mann-Whitney U test, Figure 2.15). Median flows for fistulae 
utilising the brachial artery were 1730mls/min (range 500-3680). In comparison, for 
fistulae created using the ulnar or radial arteries, median flow was 690 mls/min (range 
210-2100). 
 
Figure 2.15: Box diagram comparing fistula flow volume between fistulae sited at 
the antecubital fossa and at the wrist  
 
There was no linear correlation between DBPI and fistula volume flow; similarly, no 
linear correlation existed between DBPI and steal symptom score. DBPI was negatively 
correlated to objective score; The lower the DBPI, the higher the objective score 
observed; the correlation was weak (P < 0.001, correlation coefficient = -0.331). There 
was no association between steal symptom score and objective score (P = 0.053). 
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2.4.7 Fistula site 
When the fistula site was considered (Figure 2.16), mean digital pressures of fistulae sited 
at the wrist, ACF and distal ACF were 99 mmHg (95% CI 90-108), 90 mmHg (95% CI 
65-114) and 68 mmHg (95% CI 36-102) respectively. While there was a difference in 
mean digital pressure between these 3 groups, this was not statistically significant. There 
was a significant rise in digital pressure in each group when the fistula was occluded, and 
this was statistically significant in each case. Patients who had fistulae created in the in 
the distal ACF (utilising proximal radial / ulnar artery inflow) had the lowest mean digital 
pressure of the 3 groups. These individuals were deemed to be at high risk of steal due to 
pre-existing comorbidities and it is not surprising that this cohort’s digital pressures were 
lower.  
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Figure 2.16: Digital pressure of fistulae sited at the wrist, antecubital fossa and distal 
antecubital fossa 
ACF, antecubital fossa. Fistulae sited in the distal ACF are those that utilise 
proximal radial / ulnar artery inflow. The corresponding digital pressure when the 
fistula was occluded is displayed in the adjacent column in the same colour. The red 
line denotes the mean value of each cohort. 
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Similarly, when considering the DBPI of each cohort a similar picture is seen. All 3 
cohorts have a mean DBPI of 1 when the fistula is occluded. Mean DBPI of fistulae sited 
at the wrist, ACF and distal ACF were 0.73 (95% CI 0.67-0.79), 0.70 (95% CI 0.56-0.84) 
and 0.51 (95% CI 0.27-0.76) respectively. Whilst the DBPI of patients with antecubital 
fossa fistulae (n = 17) were lower than that of those with forearm fistulae (n = 81), this 
was not significant (P = 0.669, unpaired t-test). The difference in DBPI between the 
fistula arm and contralateral side remained even within the subgroups. 
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Figure 2.17: DBPI of fistulae sited at the forearm, antecubital fossa and distal 
antecubital fossa 
ACF, antecubital fossa. Fistulae sited in the distal ACF are those that utilise 
proximal radial / ulnar artery inflow. The corresponding DBPI when the fistula was 
occluded is displayed in the adjacent column in the same colour. The red line denotes 
the mean value of each cohort. 
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2.5 Limitations 
This prospective observational study was performed in a single institution cohort with a 
predominantly Caucasian demographic. During the study period, no patient developed 
critical hand ischaemia necessitating surgical intervention. Being an observational study, 
seven patients who were felt to be at greater risk of developing steal syndrome had had a 
proximal radial/ulnar artery to cephalic vein anastomosis created. These individuals 
might have developed more severe symptoms if a conventional brachiocephalic fistula 
had been created instead. 
2.6 Discussion 
In the vast majority of patients, digital pressures are reduced in the fistula arm, but upon 
occlusion of the fistula revert to pressures similar to that of the contralateral arm. More 
importantly, patients with low brachial pressures tended to have correspondingly lower 
absolute digital pressures, which is a phenomenon that has not been previously 
recognised. Only patients with markedly reduced digital pressures were symptomatic. 
 
Identification of individuals at risk of developing arteriovenous access ischaemic steal 
remains a challenge. It can present as a spectrum of symptoms; whilst most individuals 
experience mild discomfort with a single symptom such as cold hands, a smaller 
proportion experience a constellation of debilitating symptoms. This study attempts to 
quantify the proportion of individuals experiencing both mild and severe symptoms and 
correlate their reported symptoms with objective measurements (DP/DBPI). 
 
AVAIS is a problem experienced by a significant proportion of our cohort. Despite this, 
no individual with steal required surgical intervention. This can perhaps be attributed to 
the relatively modest cohort size. Another possible explanation might be that our cohort 
has a lower rate of distal arterial disease as compared to other populations. In mitigation, 
rates of smoking, diabetes and ischaemic heart disease were comparable to other 
published studies  [113,117–119]. What remains unknown is the long term sequlae of 
AVAIS and whether individuals with moderate symptoms eventually progress to require 
surgical intervention.  
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This study demonstrates that the DP of the fistula arm when the fistula is occluded is 
closely correlated to that of the contralateral arm; this in turn suggests that the distal 
vasculatures appear similar. This implies that there is no clinical advantage in choosing 
the laterality of the fistula’s position; for individuals who experience steal, formation of 
an identical fistula on the contralateral arm is equally likely to result in steal. Naturally, 
this is with the caveat that the underlying vasculature is similar with no arterial stenoses, 
venous outflow obstruction or previous line placement causing central venous stenosis. 
However, we recognise that positioning a fistula in the non-dominant arm is certainly 
more convenient for the patient. 
 
A low preintervention DBPI suggests inherent peripheral small vessel arterial disease, 
leading to decreased perfusion of extremities. Small vessel disease also increases 
resistance to flow and therefore flow velocities are reduced. We submit that the inherent 
quality of vessels is a major determinant of the manifestation of signs of steal. 
Furthermore, the initiation of haemodialysis can result in systemic hypotension, 
exacerbating an already diminished hand perfusion. Strategies to reduce dialytic 
hypotension will possibly decrease symptoms associated with haemodialysis access-
induced distal ischaemia [112]. 
  
We propose that recording preoperative digital pressures and DBPI may give an 
indication of the likelihood of a patient developing steal and therefore appropriate advice 
and counselling can be provided prior to the creation of an autogenous fistula. In 
individuals with existing low digital pressures an autogenous fistula might be relatively 
contraindicated. Postoperatively, our results show that, at least for our cohort, patients 
with a DP greater than 65mmHg or DBPI greater than 0.57 are unlikely to display clinical 
symptoms.  
 
The steal symptom score utilised in this study was based on a hand ischaemia 
questionnaire developed by van Hoek et al [110], which found that mild to moderate 
symptoms of steal are common in patients dialysing via autogenous fistula and that this 
was more common in individuals dialysing via BCF as  compared to those dialysing via 
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RCF (50% vs 12%). Disappointingly, there was poor correlation between the Steal 
symptoms score and DP / DBPI, implying that a linear relationship does not exist. The 
reason for this is probably due to the equal weight given to each of the five domains when 
practically the symptoms of pain and claudication represent a progression of symptom 
severity compared to coldness and paraesthesia. This makes it difficult to make any 
meaningful comparison between individuals with varying Steal symptoms scores. 
Classification using the Objective score, into the groups proposed in Table 1.2, proved to 
be far more useful. 
 
Whilst there is certainly greater blood flow in an elbow versus distal wrist fistula, in our 
cohort there was no linear correlation between flow volumes and severity of steal. 
Similarly, Hoek et al [110], reported that higher access flows were not associated with 
greater steal symptoms. This is surprising as other published literature have suggested 
that DBPI is lower in patients with fistulae in the antecubital fossa [110]. Therefore, the 
manifestation of steal is probably multifactorial and a reflection of systemic hypotension, 
relatively increased fistula flow coupled with a poor-quality distal vasculature. At our 
institution, we pursue a policy of creating radiocephalic fistulae in preference to 
brachiocephalic fistulae and therefore any individual dialysing via a brachial fistula 
would generally have had exhausted all distal options.  
 
Patients with low brachial pressures tended to have a correspondingly low digital pressure 
in both the fistula arm and contralateral arm (Figure 2.7). This poses a dilemma for the 
surgeon: creating a fistula in a hypotensive patient is more likely to exacerbate the 
problem and increase the probability of steal syndrome. A hypotensive patient’s fistula is 
also less likely to mature [120]. 
 
In conclusion, digital pressures are universally reduced in the fistula arm when an AVF 
is created. There is a linear association between low fistula-arm DBPI and low DBPI in 
the contralateral arm, suggesting that measuring DBPI prior to vascular access surgery 
may be useful in identifying patients at risk of developing critical steal syndrome. It can 
be inferred that systemic hypotension following the initiation of haemodialysis can 
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exacerbate an already diminished hand perfusion and measures preventing hypotension 
during haemodialysis will likely improve symptoms associated with haemodialysis 
access-induced distal ischaemia [112].  Once identified, these patients at risk of AVAIS 
should undergo regular post-operative digital pressure measurements as part of 
departmental policy to ensure accurate monitoring and subsequent timely surgical 
intervention if required. 
 
2.6.1 Novel Findings 
This chapter has identified several results that have not been previously recognised in the 
literature: 
Patients with low brachial pressures tended to have corresponding lower digital pressures 
(and tended to be more symptomatic). It also demonstrates that bilateral digital pressures 
are similar once the fistula is occluded. This is important as it suggests that, for patients 
that are symptomatic, placement of a similar fistula on the contralateral side is likely to 
result in comparable symptoms.  
I have demonstrated that DP and DBPI can be used as a sensitive measure for detecting 
and predicting steal syndrome. I identify that a DP of <65mmHg or DBPI <0.57 is the 
optimal point at which a patient is likely to have a positive clinical examination for steal.  
I establish that there is no linear relation between fistula flow rate and severity of steal. 
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3 RANDOMISED CONTROLLED 
TRIAL COMPARING THE 
INCIDENCE OF STEAL 
SYNDROME IN TWO TYPES 
OF ANTECUBITAL FOSSA 
ARTERIOVENOUS FISTULAE 
(STEAL TRIAL) 
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3.1 Introduction 
There are multiple modalities of haemodialysis for patients with end stage renal failure. 
Examples include arteriovenous fistula, arteriovenous graft, indwelling central venous 
catheter as well as HeRO graft (hybrid graft / indwelling catheter). Arteriovenous fistulae 
(AVF) remain the preferred form of vascular access for long-term haemodialysis in 
patients with end-stage renal failure as they are associated with the lowest risk of 
complications, lowest need for interventions and best long-term patency  [17,121]. Due 
to the rise in median ages of incident and prevalent haemodialysis patients, access-related 
ischaemia presents a significant problem in this cohort of patients. 
 
The accepted strategy in creating an AVF in the upper limb is to start at a distal site and 
should that fail, to form an AVF at a more proximal site i.e. from wrist to forearm and 
subsequently to elbow. The rationale for creating fistulae in this fashion is that it preserves 
precious venous capital. The most common type of AVF is the radiocephalic AVF sited 
at the wrist. A more proximal AVF is often created as a primary procedure when there is 
poor vasculature in the distal forearm or as a secondary procedure when a wrist fistula 
has failed. Traditionally, the brachiocephalic fistula (BCF), which involves anastomosing 
the cephalic vein to the brachial artery, has been the most common type of AVF created 
in the antecubital fossa at the elbow level. Other common types of antecubital fossa 
arteriovenous fistula (AFF) include the brachio-basilic and brachio-median cubital AVF. 
For clinicians, the temptation is to create a BCF as this tends to mature and function as a 
working fistula; avoiding multiple attempts at establishing a suitable fistula for 
haemodialysis. There is also a concern of “surgical / patient fatigue” following multiple 
attempts at fistula creation causing disillusionment and disengagement, which might 
result in patients refusing further operations and instead favouring long-term tunnelled 
catheters for dialysis. Indeed, current data suggests that patients are likely to remain with 
the first successful dialysis modality [122,123], therefore establishing a functional AVF 
in the first instance is critical. 
 
Creation of an arteriovenous fistula involves anastomosing a high pressure, high flow 
artery to a low resistance, low flow vein. The net result is the creation of a high flow, low 
resistance non-anatomic circuit [72,124,125]. There is reduced flow in the artery distal to 
the anastomosis, and consequently to the distal extremity. This phenomenon of limb 
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hypoperfusion distal to the access site is termed “steal”. In healthy vessels, there is 
dilatation of the proximal and distal arteries, compensating for enhanced systolic AV flow 
and for diastolic retrograde inflow into the fistula. Vessel remodelling takes place over 
the course of several weeks. This increase in blood flow is dramatic and is critical to 
fistula maturation [41].The individual compensates with an increase in heart rate and thus 
cardiac output. Any vascular pathology affecting these adaptive mechanisms can cause 
distal ischaemia by a steal mechanism. If a stenosis is present within the artery proximal 
to the anastomosis, less blood is delivered distally. Blood still preferentially flows into 
the low resistance fistula, leaving a reduced flow to be delivered distally. If the distal 
vessels are arteriosclerotic, this results in increased distal resistance, and blood 
preferentially travels down the low resistance path. Steal syndrome may occur 
immediately or evolve over several weeks and is often intensified during dialysis. 
Between 50-66% of patents who develop steal do so within one month of surgery 
[71,126]. 
 
As described in Chapter 1, steal is a clinical phenomenon which manifests itself in 4 
stages (Table 1.2). Asymptomatic steal (Grade 0), demonstrated by a weakened pulse, 
reduced Doppler signals and diastolic distal flow reversal on duplex ultrasound, may be 
present in the access but only become symptomatic when blood flow is shunted from 
tissue beds distal to the arterial anastomosis. The incidence of mild and moderate steal is 
unknown. Mild ischaemia (Grade I) may be self-limiting and may resolve with 
conservative management. Severe ischaemic symptoms of steal can be long-lasting and 
may be associated with constant pain, numbness, distal cyanosis or gangrene (Figure 3.2). 
Whilst symptomatic steal can occur with distal (radiocephalic) AV access, incidence is 
low, ranging from 0.25-1.8%  [75,114,127]. Severe ischaemia is most frequently 
associated with a brachial artery inflow (BCF/BBF), with frequency ranging from 4-9% 
[75,110,114]. Overall, the incidence of severe steal is 0.5-5% within the haemodialysis 
population [71,128]. Other factors associated with the development of ischaemic steal 
include diabetes mellitus, previous ipsilateral AV access, female gender and age. 
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Figure 3.1: Digital gangrene of left middle finger in a haemodialysis patient 
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3.2 Rationale of the study 
The manifestation of steal is a result of inadequate blood flow to the distal extremity. 
Utilising the proximal radial or ulnar artery instead of the brachial artery as arterial inflow 
(Figure 3.2) might be a solution to reduce the incidence of steal, which would provide an 
adequate arterial inflow to allow fistula maturation and subsequent haemodialysis while 
offering a potential option for surgical revision if the fistula eventually fails. Distal hand 
perfusion can be maintained by the concomitant arterial circulation via the palmar arch. 
There have been no randomised studies to date examining the rates of steal syndrome and 
steal phenomena in fistulae utilising brachial arterial inflow versus fistulae utilising 
proximal radial/proximal ulnar arterial inflow. Given the lack of supporting data, a state 
of clinical equipoise exists; there is genuine uncertainty as to which intervention is 
superior. 
 
3.3 Trial design 
This study is a randomised controlled clinical trial which is single blinded, intention-to-
treat and active control. The duration of candidate participation was 6 months. Figure 3.3 
details the referral pathway. Participants underwent one pre-trial consultation and 
informed consent meeting, one pre-intervention assessment and randomisation session, 
the intervention, one post-intervention telephone interview and three post-intervention 
assessments. This study procedure is further described in Section 3.8 and summarised in 
Figure 3.4. 
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Figure 3.2: Ultrasound image depicting brachial artery (BA) bifurcating into radial 
(RA) and ulnar (UA) arteries  
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3.4 Objectives and endpoints  
3.4.1 Primary objective 
This study aims to determine if patients with a fistula utilising the proximal radial/ulnar 
artery as arterial inflow have a lower incidence of steal symptoms compared to patients 
with a fistula employing the brachial artery as inflow at up to 6 months following fistula 
creation. Grading of steal symptoms would be as per Table 1.2. 
3.4.2 Primary endpoint 
The primary endpoint is the incidence of steal syndrome as measured by the Steal 
symptom score at 6 months following fistula creation. The Steal symptom score and its 
derivation has previously been detailed in Section 2.3.6. 
3.4.3 Secondary objectives 
The secondary objectives are: 
 To ascertain if there is a change in DP or DBPI before and after AFF creation and 
how this correlates to steal symptoms 
 The fistula survival rate of the two types of AFF for haemodialysis 
 The efficacy of the two study interventions in terms of complication rate 
 To incidence of severe steal requiring surgical intervention (revision/ligation) 
between the 2 study interventions 
 
3.4.4 Secondary endpoints 
The secondary outcomes are: 
 Grade of ischaemic steal syndrome 
 DP and DBPI at 3 weeks, 3 months and 6 months 
 Primary patency at 6 months 
 Complication rate, including surgical revision 
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3.5 Ethics 
3.5.1 Ethical approval 
This study was conducted in full conformity with the Declaration of Helsinki [129] and 
adhered to the standards of the International Conference on Harmonisation Good Clinical 
Practice. The protocol, informed consent form, participant information sheet was 
submitted to the Cambridgeshire 2 Research Ethics Committee, Cambridge University 
Hospitals NHS Foundation Trust and the University of Cambridge, for written approval. 
 
Ethical approval was granted by the Cambridgeshire 2 Research Ethics Committee, REC 
reference number 10/H0308/90 (refer to appendix). This study was registered with 
ClinicalTrials.gov, ID number NCT02297451. 
 
3.5.2 Confidentiality 
Trial staff ensured that participants' anonymity was maintained. This was achieved by 
only using a study specific participant ID number to identify the participant on the trial 
documentation and any electronic database. All documents were stored securely and only 
accessible by trial staff and authorised personnel. The study complied with the Data 
Protection Act and data was anonymised as soon as it was practical to do so. 
 
3.5.3 Other Ethical Considerations 
The trial did not include any vulnerable individuals or the minors; all trial participants 
were required to be able to consent freely. There was no placebo or true control group. 
All participants received one of the two trial interventions. Intervention A (BA-AFF) acts 
as the active control group. Intervention B (PRA/PUA-AFF) requires longer operative 
time and a more extensive dissection for arterial access and therefore may carry an 
increased risk of technical complications. There is insufficient data in existing studies to 
support this. We propose that the potential benefit of having a lower risk of steal 
syndrome will outweigh this risk. 
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Figure 3.3: Referral Pathway 
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3.6 Study centre 
The study was conducted in Addenbrookes Hospital, Cambridgeshire, UK. This 
university teaching hospital provides a tertiary referral vascular access service as well as 
renal transplants for East Anglia. Addenbrookes Hospital together with satellite units 
located in King’s Lynn, Bury St Edmunds and Hinchingbrooke Hospitals serve a 
haemodialysis population of approximately 400 patients. We perform approximately 200 
vascular access procedures annually. The necessary presence of clinical expertise and 
equipment required for this study is well established in our unit.  
 
3.7 Trial participants 
3.7.1 Inclusion criteria 
The study was inclusive. All patients aged ≥16 years diagnosed with end stage renal 
failure necessitating long-term haemodialysis were eligible to participate. Firstly, they 
had to be willing and able to provide informed consent for participation in the trial. 
Patients had to require an AVF in the antecubital fossa for vascular access. In terms of 
anatomy, both brachial and proximal radial (or ulnar) arteries had to be suitable (not 
severely arteriosclerotic, not stenotic, no high bifurcation, calibre >2mm) as arterial 
inflow in AVF creation when assessed via ultrasound; the patient must in theory be able 
to undergo either intervention. Similarly, the venous component of the fistula must be of 
suitable calibre (>2mm) and have sufficient length for AVF creation regardless of the 
type of fistula randomised; creation of a proximal radial (or ulnar) fistula must not 
necessitate transposition of a more distal vein which would require significantly more 
extensive dissection. 
 
3.7.2 Exclusion criteria 
Patients were excluded if a more distal fistula could be fashioned in the first instance (i.e., 
RCF or ulnarbasilic fistula [UBF]). Patients were also excluded from the study if on 
ultrasound assessment the brachial or the proximal radial / ulnar arteries were not suitable 
for fistula formation (for example, occluded with no flow on colour doppler or heavily 
calcified), or if there was insufficient length of vein extending to the territory of the 
proximal radial and ulnar arteries, making fistula formation technically unfeasible. 
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3.8 Study procedure 
3.8.1 Outline 
Each participant underwent a pre-trial consultation and informed consent meeting, a pre-
intervention assessment and randomisation session, the intervention, one post-
intervention telephone interview and three post-intervention assessments. This process is 
detailed in Figure 3.4. 
 
3.8.2 Referral to STEAL trial and consultation 
Potential participants were referred to the investigator by the vascular access surgeon 
once the decision was made to create an antecubital fossa fistula. Typically, patients 
would present following vascular assessment in the vascular access clinic, on the ward or 
via the dialysis unit. These potential participants were approached and given verbal and 
written information about the trial detailing the aims of the study, the procedure, and 
potential risks and benefits (Appendix 7.3 Participant Information Sheet). The contact 
details of the investigator was provided so that questions could be raised and concerns 
addressed before a decision was made as to whether to participate. 
 
3.8.3 Informed consent 
Following identification of suitable candidates, written and verbal information was 
provided to the patients during the first interview which detailed the nature of the study, 
any known potential risks involved and the study protocol. It was also made explicit that 
should the candidate choose not to participate in the study, that this would not prejudice 
them against any further treatment. The candidate was allowed to consider the 
information provided and ask any questions before deciding whether to participate in the 
study. 
 
Written consent was obtained at a later date once the participant has had an opportunity 
to raise any concerns. The participant signed a written consent form and a copy was given 
to the patient. The consent form was retained and filed in a secure area at the study site. 
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Figure 3.4: STEAL trial pathway 
Post-intervention Assessment (Weeks 3, 12 & 24)
This will be carried out by the investigator. The paricipant will be asked to score any steal 
symptoms and examined for sign of steal and other complications. Blood pressure 
measurement and USS will be performed by the investigator. 
Post-intervention Phone Interview (Week 1)
The participant will be phoned by the investigator at 1 week. He/she will be asked to score 
any steal symptoms. In case of severe symptoms, he/she will be brought to clinic for urgent 
examination.  
Intervention
The vascular access waiting list  coordinator will reveal the randomised intervention from 
the pre-sealed envelope and inform the operativng surgeon which intervention to perform: 
Intervention A: Brachial artery AFF or Intervention B: Proximal radial/ulnar artery AFF 
Pre-intervention Assessment
This will be done by the investigator in vascular access clinic, ward or dialysis unit. Relevant 
medical history will be obtained. Physical examination, blood pressure measurement and 
ultrasound scan of the upper limb will be carried out by the investigator. 
Consent and Randomisation
Patients who are willing to take part in the trial will be asked to sign a consent form. The 
participant will then be given a Participant ID Number. All trial data will be recorded under 
this number. The Participant ID No. is linked to a numbered envelope pre-sealed with a 
randomised trial intervention. 
Referral to STEAL Trial & Pre-trial consultation
Patients who have fulfilled the STEAL Trial inclusion criteria will be invited to meet the 
investigator where the trial procedure, risks and benefits will be explained.   
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3.8.4 Pre-intervention assessment and recruitment  
During the pre-intervention assessment, the demographic data, medical history and 
medications of the participants were recorded. Vascular assessment was then carried out 
to act as a baseline assessment and to determine the eligibility of the participant. Brachial 
blood pressure was measured using a conventional blood pressure machine. 
Measurements were also recorded from the contralateral arm.  Digital blood pressure was 
measured using the Huntleigh DopplexAssistTM (Huntleigh Healthcare Ltd, Wales, UK). 
An inflatable cuff is placed around the proximal phalynx of the index finger, with the 
sensor placed on the distal phalynx. The digital brachial pressure index (DBPI) is then 
calculated as the ratio of finger pressure to systolic blood pressure. 
 
An ultrasound assessment using the Sonosite MicroMaxx® (Fujifilm SonoSite Inc, 
Washington, USA, Figure 3.5) was used to assess the patency (patent/stenotic), size 
(>2mm) and quality (degree of arteriosclerosis) of the vessels in question. The key 
determining factor for eligibility to take part in the study stems from the assessment of 
the length of the cephalic or basilic vein. There must be sufficient length of vein to 
potentially transpose the vein to either the proximal radial or ulnar arteries. Should the 
vein be deemed not to have adequate length, then that person was deemed ineligible for 
study inclusion. Arterial duplex was not performed as this is not a routine investigation 
performed prior to AVF formation. Following inclusion, a participant ID was then 
allocated, which is linked to a randomisation number, representing the randomised 
intervention. 
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Figure 3.5: SonoSite MicroMaxx® Ultrasound System 
 
3.8.5 Randomisation 
Permuted block randomisation is used with an allocation ratio of 1:1. The randomisation 
sequence was generated at the start of the trial prior to patient recruitment by a neutral 
third party, in this case Dr Richard Parker, statistician at the Centre for Applied Medical 
Statistics from the University of Cambridge. An independent trial coordinator was 
responsible for transcribing the randomisation sequence into individual interventions and 
these were then sealed sequentially in opaque envelopes numbered according to the 
randomisation sequence. Each envelope is linked to a participant ID, and the envelope 
was opened prior to the operation. Due to the nature of the intervention, the participant 
was blinded to the intervention received, but the surgeon was not. 
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3.8.6 Intervention 
An arteriovenous fistula consists of 2 components: the arterial inflow and the venous 
outflow. This study aims to characterise the effect of the 2 different types of arterial 
inflow on steal syndrome.  
 
Participants receive one of the following study interventions: 
Intervention A (control): Fistula creation utilising the brachial artery as inflow  
Intervention B: Fistula creation using either the proximal radial artery or proximal ulnar 
artery as inflow 
 
All possible venous outflow types are included in this study. The venous outflow utilised 
will be decided by the assessing or operating surgeon at the initial vascular assessment 
depending on the patency, size of vein and its course across the antecubital fossa. 
 
The types of venous outflow include: 
1. Cephalic vein 
2. Median cubital vein 
3. Basilic vein – when this is used, the basilic vein is transposed and superficialised. 
This requires more extensive dissection. In our unit this was typically performed 
as a single stage procedure under general anaesthesia, as opposed to a two-stage 
procedure favoured by some units. 
 
The surgical procedure was performed by a total of 2 experienced consultant transplant 
surgeons and a team of senior trainees under consultant supervision. The surgeons 
generally followed a standard operating technique, using ultrasound to mark vessel 
position preoperatively and plan the appropriate incision (Figure 3.6). Almost all fistulae 
were created under local anaesthetic, with the exception of brachiobasilic fistulae. The 
vein was flushed with heparinised saline to ensure good distension. Operating loupes with 
x2.5 magnification and micro-instruments were used to form an end-to-side anastomosis. 
At the end of the operation, the operating surgeon completes a trial specific record of the 
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intervention performed. A copy of the form is included in the appendix {Section 7.5 Trial-
specific operation record (steal trial)}. 
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Figure 3.6: Creation of a proximal radial-cephalic fistula  
(A) Incision made just distal to the elbow crease at the level of the brachial 
bifurcation (B) Cephalic vein is mobilised and tributaries tied (C) Brachial artery is 
identified, radial and ulnar arteries exposed (D) End on side anastomosis created 
with good distensibility of cephalic vein evident 
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3.8.7 Follow-up post intervention 
After the antecubital fossa fistula is created, patients were evaluated on 4 occasions 
during a six-month interval (Figure 3.4).  
 
3.8.7.1 Telephone interview at week 1 
Participants were contacted and asked a list of questions to screen for symptoms of early 
steal syndrome or early postoperative complications {Appendix 7.6 Post-intervention 
assessment form (steal trial)}. If there were any concerns, the patient was brought back 
to clinic for assessment and, if required, treatment.  
 
3.8.7.2 Clinical assessments 
Following intervention, each participant was screened at 3 weeks, 3 months and 6 months.  
The following details were recorded: 
They were screened for symptoms of steal (cold extremity, pain, paraesthesia, weakness 
and claudication) and the individual score of each of these five domains are recorded 
using a visual analogue scale. The Steal symptom score is comprised of the sum total of 
these five domains. Patients were also examined for signs of steal syndrome (delayed 
capillary refill time; decreased skin temperature; pallor; decreased sensation and evidence 
of tissue loss). The grade of ischaemic steal (as outlined in Table 1.2) experienced by the 
patient was recorded. 
 
The brachial and digital blood pressures were measured. The fistula was examined for 
patency and any local complications (e.g. infection). The fistula flow rate was determined 
using duplex ultrasound. 
 
The date of first cannulation was recorded and the date of commencement of regular 
dialysis (3 consecutive dialysis sessions) was recorded  [104]. 
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3.9 Statistical Analysis 
This a single centre, single blinded randomised control trial. The active control is the 
standard treatment (brachial artery fistula [BCF/BBF]). Results are analysed on an 
“intention to treat” basis unless otherwise stated.  
Categorical variables were compared using Fisher’s exact test. Kaplan-Meier survival 
analyses and Log-rank tests were used to analyse fistula survival. In keeping with 
reporting standards recommended by the North American Vascular Access Consortium 
[36],  fistulae that failed within 72 hours were deemed to have failed at time zero. Patients 
were censored in the event of death or final measurement of patency. All analyses were 
performed with GraphPad Prism (v.5.03 GraphPad Software Inc, CA, USA). 
 
3.9.1 Sample size calculation 
From a previously unpublished pilot study performed at our institution, we calculated that 
43 patients are required in each intervention group to provide 80% power to detect a 25% 
difference in the incidence of Steal syndrome at 6-month follow up with an α = 0.05. To 
account for attrition / loss to follow up of 15%, we aim to recruit 100 patients (50 in each 
arm). 
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3.10 Interim Results 
From April 2011 - January 2017, all patients referred for creation of an antecubital fistula 
were assessed for eligibility. A total of 68 patients were recruited. The trial profile is 
detailed in Figure 3.7. Two patients were excluded; one withdrew from the study/dialysis 
and the other patient had a radiocephalic fistula created on table instead. A total of 66 
patients were randomly assigned to an intervention. Demographic data is detailed in Table 
3.1; both groups were well matched. Thirty-four patients were randomised to Intervention 
A and thirty-two were randomised to Intervention B. Sixty-five patients completed 6-
month follow up. One patient was lost to 6-month follow up.  
 
3.10.1 Steal symptom score at 6 months 
At 6 months, there was no significant difference in the scores of both groups (Figure 3.8, 
P = 0.585, Mann-Whitney U test, intention to treat analysis). There was no significance 
difference in subgroup scores between both interventions (Figure 3.9). When the analysis 
considered the actual intervention performed, this did not reveal any significant 
difference between both interventions. 
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Figure 3.7: Trial Profile 
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 Entire Cohort 
(N = 66) 
Intervention A 
(N = 34) 
Intervention B 
(N = 32) 
P valuea 
Age years  mean (SD) 69 (11.3) 67 (12.8) 71 (9.4) 0.183b 
Gender m:f 32:34 19:15 13:19 0.215 
     
Comorbidities     
Ischaemic heart disease 19 (30.6) 11 (32.4) 8 (25.0) 0.592 
Hypertension 29 (43.9) 15 (44.1) 14 (43.8) 0.976 
Diabetes 
Total (%) 
Type I 
Type II 
 
21 (31.8) 
3 (4.5) 
19 (28.8) 
 
13 (38.2) 
2 (5.9) 
11 (32.4) 
 
9 (28.1) 
1 (3.1) 
8 (25.0) 
 
0.384 
Smoking history 
Smoker (%) 
Ex-smoker (%) 
Non-smoker (%) 
 
11 (16.7) 
6 (9.1) 
49 (74.2) 
 
6 (17.6) 
2 (5.9) 
26 (76.5) 
 
5 (15.6) 
4 (12.5) 
23 (71.9) 
0.644 
Peripheral vascular disease (%) 5 (7.6) 4 (11.8) 1 (3.1) 0.357c 
     
Aetiology of Chronic Kidney Disease 
Diabetic nephropathy (%) 10 (15.2) 7 (20.6) 3 (9.4) 0.306c 
Urological disease (%) 8 (12.1) 2 (5.9) 6 (18.8) 0.143c 
Glomerulonephritis (%) 5 (7.6) 3 (8.8) 2 (6.3) 1.000c 
Hypertensive nephropathy (%) 5 (7.6) 3 (8.8) 2 (6.3) 1.000c 
Adult polycystic kidney 
disease (%) 
4 (6.1) 2 (5.9) 2 (6.3) 1.000c 
Idiopathic (%) 21 (31.8) 13 (38.2) 8 (25.0) 0.297 
Other (%) 13 (19.7) 9 (26.5) 4 (12.5) 0.154 
Table 3.1: Demographics and comorbidities 
a All p values were calculated via χ2 test unless otherwise stated, comparison made 
between Intervention A and B; b unpaired t-test; c Fischer’s exact test 
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Figure 3.8: Steal symptom score distribution at 6 months (Intention to treat analysis) 
 
 
Figure 3.9: Subgroup breakdown  
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3.10.2 Distribution of steal symptoms in the cohort 
The distribution of grade of steal according to intervention randomised is detailed in 
Figure 3.10. The maximal symptom score during the 6-month study interval was used. 
Twenty-four patients in the cohort were asymptomatic (9 received intervention A and 15 
received intervention B). A further nineteen displayed mild symptoms of steal (Grade 1). 
When comparing asymptomatic (Grade 0) to symptomatic patients (incorporating mild 
and severe symptoms [Grades 1-4]) in both interventions, there was a significant 
difference (P = 0.0381, Fischer’s exact test). The χ2 test could not be used in this instance 
to analyse for each individual category (0-4) as χ2 calculations are only valid when all 
expected values are greater than 1 and at least 20% of the expected values are greater than 
5. Therefore, they were grouped as such. The difference between both interventions is 
more striking when we consider largely asymptomatic patients (Grades 0-1) versus 
patients with more severe and debilitating symptoms (Grades 2-4). This second analysis 
was performed because, as clinicians we would be more concerned with patients 
presenting with moderate to severe symptoms (Grades 2-4), and further deterioration 
might require intervention. There is a significant difference between both interventions 
(P = 0.0024, Fischer’s exact test).  
 
Whilst Intervention B still results in a degree of ischaemia resulting in cold hands, it 
appears that the more debilitating symptoms of steal are less likely to manifest. When 
considering the actual intervention performed rather than an “intention-to-treat” analysis, 
the results remain significant (P = 0.0332 and P = 0.0059 respectively, Fischer’s exact 
test).  
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Figure 3.10: Distribution of grade of steal by type of intervention (Intention to treat 
analysis) 
 
3.10.3 DP, DBPI and grade of steal 
Pre-operatively, there was no significant difference in the DP and DBPI of both 
interventions (Figure 3.11 and Figure 3.12, P = 0.259 and P = 0.124 respectively, Mann-
Whitney U test). When comparing the pre-intervention DP to the DP at 3 weeks, there 
was a significant difference (P = 0.001 and P = 0.0006, Intervention A and Intervention 
B respectively, Wilcoxon matched-pairs signed rank test). The median reduction in DP 
following operation was 23mmHg in Intervention A and 29mmHg in Intervention B, but 
this was not statistically significant (P = 0.652, Mann-Whitney U test). Similarly, there 
was a reduction in DPBI postoperatively, with the mean DBPI reduction in Intervention 
A of 0.18 and in intervention B of 0.25, this reduction however was not significant (P = 
0.401, unpaired t-test).  
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Figure 3.11: Distribution of DP for both interventions at various time points 
Error bars denote standard deviation and black line denotes mean 
 
Figure 3.12: Distribution of DBPI for both interventions at various time points 
Black line denotes mean 
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When the pre-operative DP of the cohort was graphed against the eventual grade of steal 
experienced (Figure 3.13), there was a clear trend in lower pre-operative DP giving rise 
to more severe grades of steal. This trend was also similar when considering the 
preoperative DBPI (Figure 3.14). There was a solitary individual who had experienced 
grade 4 steal, necessitating surgical intervention. 
 
 
Figure 3.13: Pre-intervention DP and associated grade of steal 
(A) Total cohort (B) Intervention A (C)Intervention B 
The centre dot represents the mean and the error bars denote the standard 
deviation. Note that in graphs A and B, there was a single individual who 
experienced grade 4 steal. In graph C, no individuals experienced grade 3 or grade 
4 steal. 
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Figure 3.14: Pre-intervention DBPI and associated grade of steal 
(B) Total cohort (B) Intervention A (C)Intervention B 
The centre dot represents the mean and the error bars denote the standard 
deviation. Note that in graphs A and B, there was a single individual who 
experienced grade 4 steal. In graph C, no individuals experienced grade 3 or grade 
4 steal. 
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Comparing the post-operative DBPI of all patients to the grade of steal experienced, there 
is a clear trend of decreasing DBPI as severity of steal increases (Figure 3.15). When 
comparing the post-operative DBPIs of largely asymptomatic patients (Grades 0-1) 
versus patients with more severe and debilitating symptoms (Grades 2-4), there is a 
significant difference of the DBPI between both groups (P < 0.0001, unpaired t-test).  
 
 
Figure 3.15: Post intervention DBPI and associated grade of steal of all patients  
The centre dot represents the mean and the error bars denote the standard 
deviation.  
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Finally, when the cohort was stratified according to eventual grade of steal experienced 
(Figure 3.16), it can be seen that individuals who experience more severe grades of steal 
(grades 2-4) generally have a lower DP (mean difference 23mmHg) and DBPI (mean 
difference 0.13) preoperatively when compared to those who were asymptomatic or had 
mild symptoms, and this was statistically significant (P = 0.034 and P = 0.041 
respectively, unpaired t-test).   
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Figure 3.16: Cohort distribution of DP and DBPI according to grade of steal 
(A) DP – Steal grade 0-1 (B) DP – Steal grade 2-4 (C) DBPI – Steal grade 0-1  
(D) DBPI – Steal grade 2-4     
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3.10.4 Fistula survival 
Six months outcomes are detailed in Table 3.2 – for Intervention A, 23 fistulae remained 
functional and in use; For Intervention B, 22 fistulae remained patent. There was no 
significant difference in six-month outcomes between both interventions (Table 3.2, χ2 
test, P = 0.964). 
 
When considering fistula survival over 6 months, there was no significant difference in 
fistula survival between both interventions (P = 0.630, Log-rank test, intention to treat 
analysis, Figure 3.17). This also held true when considering the actual intervention 
performed (P = 0.633, Log-rank test, Figure 3.17). 
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Intervention A  
(n = 34) 
Intervention B  
(n = 32) 
χ2 test 
Functional 23 (67.6%) 22 (68.8%) 
 P = 0.964a 
Thrombosed 6 (17.6%) 6 (18.8%) 
Failed to mature 0 1 (3.1%) 
Not used (unrecognised 
central venous stenosis) 
1 (2.9%) 0 
Patient death / withdrawn 
from haemodialysis 
3 (8.8%) 3 (9.3%) 
Intervention for Steal 1 (2.9%) 0 
 
Table 3.2: 6-month outcome of interventions 
a For the purpose of χ2 analysis integer values in the categories failed to mature, not 
used, patient death and intervention for steal were combined for each intervention. 
This is because χ2 calculations are only valid when all expected values are greater 
than 1. 
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Figure 3.17: 6-month survival (Primary patency) of fistulae according to 
intervention   
Patients who died were censored at time of death. 
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3.10.5 Complications and patient mortality 
One of our concerns while the trial was ongoing was the complication rate with respect 
to Intervention B; that failure of the fistula might result in patients being unable to receive 
a further, more proximal fistula on the ipsilateral side. One patient in intervention B had 
a fistula which failed to mature sufficiently to be utilised for haemodialysis. One patient 
in Intervention A had a functional fistula which was not utilised due to unrecognised 
central venous stenosis. A total of six patients died or were withdrawn from 
haemodialysis (3 patients from each intervention arm) during the study interval (Table 
3.2).  
 
Finally, one individual from Intervention A had a revision using distal inflow (RUDI). 
This patient had a background of diabetic nephropathy causing ESRF, type 2 diabetes, 
hypertension, previous stroke and peripheral vascular disease. Preoperatively, he had a 
DBPI of 0.84 and steal symptom score of 0. Clinical examination at that point did not 
give any indication of digital ischaemia. Over the course of 3 months following formation 
of a brachiocephalic fistula, he developed severe symptomatic steal, with an unrecordable 
digital pressure / DBPI, and subsequently underwent a RUDI procedure which resolved 
his symptoms. 
  
Chapter 3: Randomised controlled trial comparing the incidence of steal syndrome in two types of 
antecubital fossa arteriovenous fistulae (STEAL trial) 
   97 
3.11 Limitations 
The current results presented are a result of an interim analysis. Only participants were 
blinded to the type of operation carried out, as the intervention would become apparent 
to the assessor during ultrasonic assessment of the fistula. This might create ascertainment 
bias, which is minimised by using a symptom score which is provided by the “blinded” 
patients prior to the ultrasonic assessment outlined above and by using absolute 
measurements in other elements during the post-intervention assessment. 
 
Determination of fistula flow was performed using repeated ultrasonic measurement, 
however readings were difficult to reproduce for a variety of reasons – patient position, 
the turbulent flow inherent at the arteriovenous junction, compressibility of the venous 
component despite arterialisation, and inter-operator variability. Nevertheless, access 
flow measurements had minor relevance for the diagnosis of steal syndrome as, 
depending on the severity of arterial disease, symptoms can occur at any rate of access 
flow. This study did not have access to a dedicated vascular scientist and therefore in-
depth arterial assessments or waveform analysis using doppler ultrasound could not be 
performed. 
 
3.12 Discussion 
Severe hand ischaemia as a consequence of arteriovenous steal is rare and seldom requires 
surgical intervention [110]. The incidence of steal phenomena is unknown; it is likely 
under-reported despite affecting a large proportion of patients on haemodialysis. This is 
possibly due to steal phenomena manifesting at a lower severity and therefore dismissed 
as a mild annoyance, bearable and not requiring intervention. As a result, few studies 
have solely focused on the occurrence of this phenomena.  
 
In retrospect, utilising the Steal symptom score at 6 months as the primary endpoint was 
not ideal. Although it had previously been published, it had not been extensively 
validated. The sample size calculation was based on a previous unpublished pilot study 
that had estimated the expected incidence of steal in Intervention A and Intervention B to 
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be 30% and 5% respectively which was perhaps overly optimistic. To compound the 
issue, patient attrition in the form of thrombosed fistula, patient death or withdrawal of 
haemodialysis meant that these individuals were not included in the 6-month Steal 
symptom score analysis detailed in Section 3.10.1. The degree of attrition should have 
been factored into the sample size calculation to a greater extent. Instead, we should have 
considered a broader, more inclusive primary endpoint, using the grading system 
proposed by Tordoir et al [75], which mirrors the classification used in the grading of 
lower limb ischaemia. 
 
In this study, the classification of each patient’s ischaemic symptoms was not blinded. 
Nevertheless, our results demonstrate that a majority of patients dialysing via antecubital 
fossa fistula experience some degree of steal and this has not been widely appreciated in 
the published literature. Our data suggests that 73.5% of patients that were randomised to 
Intervention A had an element of steal phenomena (Grade 1-4), and 47.1% had more 
severe symptoms (Grades 2-4). In comparison, for Intervention B,  46.4% had elements 
of steal phenomena (Grades 1-4) with 10.7% having severe symptoms (Grades 2-4). In 
our entire cohort of patients, 19 (30.6%) had mild symptoms (Grade 1), which would not 
have ordinarily been picked up in scheduled dialysis sessions. A total of 38 patients 
(61.3%) experienced some degree of steal phenomena, albeit that this tended to be skewed 
towards the less severe side of the spectrum. From existing published series, the estimated 
incidence of symptomatic ischaemia ranges from 2-8 percent of the haemodialysis 
population [107]. In our cohort, 19 (30.6%) patients experienced more debilitating 
symptoms of steal, with 3 patients experiencing rest pain and/or tissue loss. In this study 
only 1 patient required operative intervention in the form of a RUDI to ameliorate severe 
steal. 
 
The Steal symptom score was not particularly useful clinically as previously mentioned 
in the discussion in Chapter 2 – primarily because it assumes that all 5 variables are 
weighted equally, when in fact they represent a progression of ischaemic symptoms from 
coldness to weakness and altered sensation and finally to cramp and pain. This lends the 
possibility that patients with similar steal symptom scores might experience very different 
symptom severity, making it challenging to make any meaningful comparisons. The basis 
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of the steal symptom score is the visual analogue scale (VAS), which was initially 
developed to measure subjective phenomena such as emotion and mood [130]. It has 
since been employed as a measurement scale for several fields, most notably pain. While 
the VAS has been widely recognised as the most feasible and acceptable of health state 
evaluations, it does suffer from limitations – most notably a “ceiling effect”. This can 
conceal variations in severity and/or intensity, causing compression of these ratings. In 
reality, the majority of patients reported within a narrow range of scores, making it 
difficult to ascertain any changes in their symptom severity over the course of the six-
month study period [130,131]. At six months, there was no significant difference in the 
mean Steal symptom score in both cohorts, nor was there a significant difference in the 
subgroup scores (Figure 3.8 and Figure 3.9).  
 
Recruitment of patients for the trial proved to be challenging. Despite identifying and 
recruiting all possible patients during the study interval where an antecubital fossa was 
deemed necessary, numbers remained small, with only one or two patients recruited per 
month. This resulted in several extensions to the study duration. The primary reason for 
this was the success of our radiocephalic fistula programme, which furnished individuals 
for functional distal fistulae with good patency, mean that patients requiring an 
antecubital fossa fistula would have necessarily exhausted all distal upper arm options. 
The net result was a small pool of suitable patients requiring an antecubital fossa fistula. 
Since the incidence of steal in proximal radial/ulnar fistulae is unknown whereas it is 
documented  for brachiocephalic fistulae, there could be an argument for using an unequal 
allocation, perhaps 2:1 or 3:1. This might allow for more information on primary and 
secondary outcomes to be gained for the intervention [132]. However, unequal allocation 
would require the recruitment of a larger cohort to achieve the same level of statistical 
power [133].   The very same successes with our distal fistula programme led to the 
retrospective examination detailed in Chapter 4, where we challenged the premise that 
elderly individuals commencing haemodialysis would be better served with a brachial 
fistula rather than a fistula sited distally at the wrist. 
   
The purpose of this trial was to investigate the hypothesis that patients with a fistula 
utilising the proximal radial/ulnar artery as arterial inflow (Intervention B) have a lower 
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incidence of steal symptoms compared to patients with a fistula using the brachial artery 
as inflow. From the demographic data in Table 3.1, both cohorts were comparable, with 
similar comorbidities. Despite this, the cohort randomised to Intervention B experienced 
a statistically significant reduction in steal symptoms as compared to patients randomised 
to Intervention A. This observation also held true when the cohort was reanalysed 
considering the actual intervention performed. The post-operative assessment of steal and 
its grading was based on clinical assessment and therefore is observer-dependent. 
Consequently, there might be unconscious observer bias. This was minimised firstly by 
asking the “blinded” patients to rate the severity of their symptoms on a visual analogue 
scale and secondly by performing the assessment prior to any ultrasonic examination, 
which would confirm the actual fistula created. Certainly, the data does support our 
hypothesis.  
 
Preoperative measurements of digital pressures may help to identify patients at risk of 
developing steal. Patients that had low initial (preoperative) digital pressures / DBPI 
tended to develop more severe grades of steal (Figure 3.16), however there is no strict 
DBPI threshold below which steal is inevitable. During preoperative assessment, both 
randomised cohorts had similar DBPI, and certainly postoperatively we observed that 
patients randomised to Intervention A had lower DBPI as compared to those randomised 
to Intervention B (Figure 3.15). Overall, perhaps unsurprisingly, patients with lower 
postoperative DBPI experienced a greater severity of steal symptoms (Figure 3.15). 
 
A vascular access surveillance programme utilising digital and brachial blood pressure 
measurements would present a low cost, highly effective way of identifying patients with 
steal phenomena and symptomatic steal, whereby early intervention could be considered 
to halt the progression to more severe symptoms. In Chapter 2, we had established using 
ROC curve analysis and Youden’s J statistic that the optimum cut off DBPI for 
experiencing a clinical symptom of steal was 0.57. This finding appears to be supported 
in Figure 3.15, but larger cohort studies are required before a definitive answer can be 
provided. Each participant was monitored for 6 months after fistula creation, and 
therefore patients who developed ischaemic steal symptoms after the study period were 
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not formally captured in the study; we intend to report this data in once the study 
concludes. 
 
During the study interval, six patients died or were withdrawn from haemodialysis. 
Whilst the decision to create an arteriovenous fistula is multidisciplinary involving 
nephrologists, vascular access nurses and access surgeons, it highlights the need for better 
markers or indicators to identify patients who are physiologically deteriorating, so that 
appropriate renal replacement therapy can be instituted.  
 
This study has shed some light on symptomatic steal and steal phenomena which is 
currently underdiagnosed and therefore under-reported. Current diagnosis and treatment 
appear to be inadequate. Our results suggest that if several risk factors for steal are present 
pre-dialysis (diabetes, hypertension, ischaemic heart disease), particularly in the presence 
of low finger pressures, it would be prudent to consider the creation of a PRCAVF / 
PUCAVF fistula in preference to a BCF. When ischaemia is suspected, adequate 
diagnosis and timely intervention is necessary to avoid tissue loss. This study aims to 
generate more interest in this condition and foster a better understanding amongst 
physicians and surgeons alike – that we would be more vigilant in diagnosing steal and 
steal phenomena, and as a result, be able to keep these patients under surveillance and 
deliver better quality care to our patients, improving their lives for the better. 
 
3.12.1 Further work 
Patients were only followed up for a period of 6 months. As such, the longevity 
(primary/secondary patencies) of a proximal radial/ulnar fistula is yet to be determined; 
current data would suggest that it is comparable (Figure 3.17). Following completion of 
the study, the long-term patencies of these fistulae can be determined.  
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3.12.2 Novel Findings 
In this chapter, I determine: 
The incidence of steal phenomena and steal syndrome (grades 1-4) for patients with a 
BCF is 73.5%. For more severe symptoms (grades 2-4) the incidence is 47.1% (Section 
3.10.2). The incidence of mild steal (steal phenomena) is unknown in current literature 
and the manifestation of moderate to severe symptoms in our cohort is much higher than 
has previously been reported in the literature. To my knowledge, this is the first report to 
classify incidence of steal according to grade of severity. 
I establish that utilising the proximal radial/ulnar artery as arterial inflow for fistula 
creation results in significantly lower incidence of steal and steal phenomena. In our 
cohort, patients receiving Intervention B were less likely to experience the more 
debilitating symptoms of steal (Figure 3.10). The complications rates and 6-month fistula 
survival for both interventions are comparable (Sections 3.10.4 and 3.10.5).    
I also identified that regardless of intervention performed, lower pre-operative DP / DBPI 
was likely to give rise to more severe grades of steal (Figure 3.13 and Figure 3.14). 
Similarly, as expected, the postoperative DBPI is inversely related to the grade of steal 
experienced; a low DPBI would suggest more severe symptoms (Figure 3.15). This 
relationship whilst obvious is not widely appreciated in the vascular access literature.  
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4 OUTCOMES OF PRIMARY 
ARTERIOVENOUS FISTULAE 
IN ELDERLY PATIENTS 
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4.1 Introduction 
As the population ages, the incidence of end-stage renal failure (ESRF) is increasing 
[134], resulting in more elderly patients being considered for haemodialysis. More than 
80% of all patients worldwide who receive treatment for renal failure live in affluent 
countries with good access to healthcare and large elderly populations [135]. It is 
estimated that one in five men and one in four women between the ages of 65 and 74, and 
half of people over the age of 75 have chronic kidney disease [136]. In the UK, the median 
age of the incident haemodialysis population has increased from 61 in 1997 to 66.9 in 
2012, and in 2000, 19.2% of haemodialysis patients were older than 70, whereas for 2012 
that figure is 24.9% [137,138]. 
 
Provision of vascular access in elderly haemodialysis patients is undoubtedly 
challenging, with relatively little data published to inform decision making 
[45,117,134,139–142]. Current guidelines from the National Kidney Foundation Kidney 
Disease Outcomes Quality Initiative (NKF-KDOQI), the Society of Vascular Surgery, 
and the United Kingdom Renal Association [20,143,144] do not distinguish elderly 
haemodialysis patients as a separate cohort. All recommend that in order to preserve 
proximal sites for future access attempts, arteriovenous fistulae are sited as distally as 
possible in the upper extremity, with the implication that where possible, radiocephalic 
fistulae should be performed as first choice for dialysis access in the elderly. 
Nevertheless, on the basis that preservation of venous capital is less of a concern due to 
the limited life-expectancy of elderly haemodialysis patients, allied to the consideration 
that patency rates for radiocephalic fistulae in this cohort may be lower [45,117], several 
authors have advocated that antecubital (brachiocephalic (BC) and brachiobasilic (BB)) 
fistulae should instead be considered the first option [45,145,146]. Complication rates for 
antecubital fistulae are, however, higher than for wrist fistulae, and in particular, the 
incidence of hand ischemia from steal syndrome is approximately ten-fold higher for 
fistulae created in the antecubital fossa [73,75,76]. Similarly, survival rates for elderly 
dialysis patients are improving [147]. Hence, consensus as how to best provide 
haemodialysis access for elderly patients with ESRF has not been reached [148].  
 
On the basis that fistulae formed using small veins are less likely to mature [149–151], 
many centres create radiocephalic (RC) fistulae only if the cephalic vein is at least 2.5mm 
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or 3mm in diameter. However, this generally results in the majority of fistulae being sited 
in the antecubital fossa [37,152,153]. In comparison, our strategy for vascular access 
provision has focused on maximizing the numbers of RC fistulae created. Irrespective of 
vessel size, we create a RC fistula if the radial artery and cephalic vein at the wrist are 
judged clinically suitable [104,154]. Using this strategy, we fashion RC fistulae in over 
80% of patients, with one year patency rates of 77% [154]. We adopted the same approach 
for provision of permanent vascular access in elderly haemodialysis patients, principally 
because of concerns that antecubital fistulae would carry a higher risk for development 
of steal syndrome. Here we report a large single centre retrospective cohort study 
describing provision of vascular access surgery for haemodialysis patients aged over 70. 
Contrasting previous reports [117], RC fistulae were created successfully in the majority 
of patients, with acceptable maturation and patency rates and with a low incidence of 
complications. 
 
4.2 Methods 
4.2.1 Patients  
All consecutive patients aged 70 and above who had a primary arteriovenous fistula 
created between 1st January 2005 and 31st Dec 2012 in Addenbrooke’s Hospital were 
identified from our prospectively maintained vascular access database. All cases were 
retrospectively cross-referenced to theatre records. Incident haemodialysis patients who 
had a primary RC, BC or BB fistula created as their first option for permanent 
haemodialysis access were included in the analysis. No prosthetic grafts were used as 
first-line vascular access in our cohort.  
 
Case notes were examined for operative details. Data was analysed until cessation of 
follow-up on 30 June 2013. 
 
4.2.2 Preoperative assessment and initial AVF creation 
Our unit has previously demonstrated that clinical examination can suffice in certain 
instances [154]. Patients underwent preoperative clinical assessment, with Doppler 
ultrasound (FUJIFILM SonoSiteTM) performed as an adjunct to clinical examination. In 
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these cases, the diameters of the vessels of interest were recorded. In accord with our 
previous publication [154], we did not employ a threshold value for the diameter of the 
wrist cephalic vein below which a radiocephalic fistula was not attempted, and were 
prepared to create fistulae with cephalic vein diameter less than 2.5mm if the vein was 
deemed clinically to be of good quality [154]. Where clinically indicated, patients thought 
at risk of central venous stenosis were imaged preoperatively using magnetic resonance 
or computerised tomography. Fistulae were created by a consultant surgeon with a special 
interest in vascular access and a team of transplant registrars. Both primary fistulae and 
proximal revisions were performed by the same team. 
 
4.2.3 Description of surgical technique 
Almost all fistulae were created under local anaesthetic, with exception of BB fistulae, 
which were created as a single stage procedure under general anaesthesia. Heparinised 
saline was used to distend the vein prior to anastomosis, and an end-to-side anastomosis 
was created with 6-0 or 7-0 prolene. Antiplatelet agents (generally aspirin) were 
continued in the postoperative phase. Radiological salvage of a failed radiocephalic 
fistula was not available during the study period; secondary patency rates therefore reflect 
only operative salvage through formation of a proximal neo-anastomosis [104]. 
 
4.2.4 Outcome and statistical analysis 
Patients who had an arteriovenous fistula created but did not proceed to require 
haemodialysis were excluded from further analysis. Categorical variables were compared 
using Fisher’s exact test. Kaplan-Meier survival analyses and Log-rank tests were used 
for fistula survival and for patient mortality. Kaplan-Meier analysis was performed on an 
intention to treat basis, as outlined by Sidawy et al [30]; fistulae that failed within 72 
hours were deemed to have failed at time zero. All analyses were performed with 
GraphPad Prism (v.5.03 GraphPad Software Inc, CA, USA). Patients were censored in 
the event of death or final measurement of patency. 
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4.3 Results  
4.3.1 Patient Cohort  
Between 1st January 2005 and 31st December 2012, 304 patients aged over 70 were 
referred for creation of permanent haemodialysis vascular access. At referral, 52.3% of 
patients were pre-dialysis; the remainder were dialysing via a central venous catheter 
(CVC). Patient demographics of those that commenced haemodialysis during the study 
period are detailed in Table 4.1: 67.8% of patients were male, 67.8% were receiving anti-
hypertensive medication, and 24.3% were diabetic.   
 
 
Primary RC fistula 
(n = 204) 
Primary antecubital 
fistula (n = 10) 
P valuec 
Age (years)a 78 (4.92) 76 (4.49) 0.35d 
Gender male (%)b 141 (69.1) 4 (40.0) 0.08e 
Anastomosis site 204 RC 9 BC 
1 BB 
 
Hypertension (%) 139 (68.0) 6 (60.0) 0.73e 
Diabetes (%) 49 (24.0) 3 (30.0) 0.71e 
Predialysis (%)b 67(32.8) 2 (20.0) 0.51e 
 
Table 4.1: Patient Characteristics 
RC, radiocephalic; BC, brachiocephalic; BB, brachiobasilic 
a Values are mean (SD); b Patients already established on dialysis were dialyzing 
through central venous catheter c Comparison made between RC and BC fistulae    
d Mann-Whitney U test; e Fisher’s exact test 
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4.3.2 Provision and Outcomes of Haemodialysis Access Surgery  
As detailed in Figure 4.1, of the 304 primary access procedures performed, 293 (96.4%) 
RC and 11 (3.6%) antecubital (10 BC and 1 BB) arteriovenous fistulae were created; no 
arteriovenous grafts were formed. Ninety (29.6%) patients remained pre-dialysis and 
were excluded, leaving the remainder (204 RC, 9 BC, 1 BB fistulae) as a cohort for further 
analysis. Patency rates for these fistulae are detailed in Table 4.2, which shows that 
primary maturation rates and one-year primary patency rates were similar for RC and BC 
fistulae, albeit direct comparison is difficult due to the small number of BC fistulae 
created as a primary procedure. Twenty-five RC and two BC fistulae experienced 
immediate failure (12.3% and 22.2% respectively, P = 0.319, Fisher’s exact test). 
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Figure 4.1: Outcome of patients over 70 referred for creation of permanent 
haemodialysis access. 
RCF, radiocephalic fistula; BCF, brachiocephalic fistula; BBF, brachiobasilic 
fistula 
  
Chapter 4: Outcomes of primary arteriovenous fistulae in elderly patients 
   110 
 
Primary RC fistula  
(n = 204) 
Primary antecubital fossa fistula 
(n = 10) 
BC (n = 9) BB (n = 1) 
Achieved maturity 
and subsequently 
used for dialysis 
(%) 
 
130 (63.7) 5 (55.6) 1 
Immediate failure 
(%) 
 
25 (12.3) 2 (22.2) 0 
Median primary 
patency in months 
(range) 
 
12.9 (0-97.4) 5.3 (0-47.1) 2.8 
Median secondary 
patency in months 
(range) 
 
33.4 (0-97.4) 6.7 (0-47.1) 2.8 
Table 4.2: Patency rates of patients who proceeded to haemodialysis 
RC, radiocephalic; BC, brachiocephalic; BB, brachiobasilic 
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For those patients whose fistula failed to mature (49 RC and 2 BC fistulae, 24.0% and 
22.2% respectively), subsequent access interventions are detailed in Table 4.3. Eight 
patients with RC fistulae declined further fistula creation and elected to dialyse via a 
central line. Operative salvage was attempted in 18 RC fistulae that had failed to mature, 
by creating a more proximal neo-anastomosis [104]. This proximal revision was 
successful in 15 patients. During the study period, a further 33 wrist fistulae that had 
achieved functional patency were salvaged successfully upon failure by formation of a 
proximal neo-anastomosis. As a consequence of early and late operative salvage of failed 
RC fistulae, one-year secondary patency rates for wrist fistulae were significantly higher 
than primary patency rates (66.0% vs 54.3%, P = 0.027, Log-rank test, Figure 4.2). 
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Subsequent access 
interventions 
Failed to achieve maturity (number) 
Radiocephalic fistulae 
(49 of 204) 
Brachiocephalic fistulae 
(2 of 9) 
Proximal neo-anastomosis 
 
18 0 
Refused further surgery 
 
8 0 
Further primary wrist 
fistula 
 
12a 2b 
Further primary 
brachiocephalic  fistula 
 
11 0 
Table 4.3: Outcome of fistulae which failed to achieve maturity 
a 7 contralateral radiocephalic fistulae, 3 ipsilateral ulnarbasilic fistulae and 2 
ulnarcephalic fistulae  
b 2 ipsilateral radiocephalic fistulae 
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Figure 4.2: Survival of radiocephalic (RC) and brachiocephalic (BC) fistulae  
*  For radiocephalic fistulae, one-year secondary patency rates were higher 
than primary patency rates (P = 0.027, Log-rank test).  
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4.3.3 Effect of cephalic vein diameter on fistula patency 
Our approach to haemodialysis provision differs from other centres in that we do not 
adopt a minimum cut-off value for the diameter of the cephalic vein, below which a 
radiocephalic fistula is not attempted. Pre-operative ultrasound measurements of the 
diameter of the cephalic vein were recorded for 166 of the 204 wrist fistulae created 
(81.4%), and of these, 39 (23.5%) had radiocephalic fistulae formed using cephalic veins 
less than 2.5 mm in diameter. Although immediate failure rates of these fistulae were 
comparable for radiocephalic fistulae created using cephalic veins greater than 2.5mm in 
diameter (15.4% vs 13.4%, P = 0.79, Fisher’s exact test, Figure 4.3), one year primary 
patency was poorer (40.9% vs 58.2%, P = 0.015, Log-rank test, Figure 4.3). As a result 
of salvage through formation of a proximal neo-anastomosis, secondary patency rates 
were greater, albeit still poorer than was achieved for fistulae created using cephalic veins 
≥2.5mm (48.6% and 71.6%; P = 0.005, Log-rank test, Figure 4.3).   
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Figure 4.3: Patency of radiocephalic fistulae stratified according to cephalic vein 
(CV) size 
*  Primary patency at one year was poorer in radiocephalic fistulae utilizing 
CV <2.5mm as compared to those with CV >2.5mm (P = 0.015, Log-rank test) 
**  Secondary patency rates of radiocephalic fistulae created with CV <2.5mm 
was poorer than those using CV>2.5mm (P = 0.005, Log-rank test) 
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4.3.4 Patient age and fistula patency 
Although the immediate failure rates of radiocephalic fistulae formed in patients aged 
between 70 and 80 was lower than those formed in patients over 80 years old, this was 
not statistically significant (9.9% vs 16.4%, P = 0.19, Fisher’s exact test, Figure 4.4). 
Two-year secondary patency rates for these groups were also not statistically different 
(57.3% vs 44.2%, P = 0.114, Log-rank test, Figure 4.4). 
 
 
Figure 4.4: Primary and secondary patency of radiocephalic fistulae stratified 
according to age  
* Two-year secondary patency for these groups were not statistically 
significant (P = 0.066, Log-rank test). 
NS, not significant 
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4.3.5 Establishment of haemodialysis 
As can be seen from Table 4.4, which reports the dialysis mode one year after creation of 
the first radiocephalic fistula, 69.6% of those patients which were dialysing did so via a 
wrist fistula, with a relatively low percentage (24.3%) dialysing via a central line. Thus, 
despite an immediate failure rate of >30% for wrist fistulae in the elderly, the additional 
salvage operations required (mean 1.38 per patient) do not appear to lead to delays that 
ultimately increase the reliance on dialysis via a central line. As additional support, of the 
159 pre-dialysis patients that underwent autogenous fistula formation, 69 (67 RC + 2 BC 
fistulae; 43.4%) proceeded to require haemodialysis during the study period. Of these, 65 
(94.2%) avoided central line catheterisation and initiated haemodialysis via their fistula, 
with a median time of 8 months (range 0-60) from referral to initiating dialysis. 
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Disposition n % 
Radiocephalic fistula 
 
82 40.2 
Tunneled central line 
 
36 17.6 
Predialysis 
 
29 14.2 
Proximal radiocephalic fistula 
 
20 9.8 
Death 
 
18 8.8 
Brachiocephalic fistula 
 
9 4.4 
No longer required dialysis 
 
8 3.9 
Ulnarcephalic fistula 
 
1 0.5 
Dialysis discontinued (subsequent death) 
 
1 0.5 
Table 4.4: Outcome and dialysis mode 1 year after creation of primary radiocephalic 
fistula 
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4.3.6 Complications and Patient Mortality 
One of the major concerns underlying our strategy of focusing on the creation of distal 
(radiocephalic) fistulae was the potential for development of steal syndrome following 
formation of antecubital (BC and BB) arteriovenous fistulae in the elderly. A total of 298 
vascular access procedures were performed on the elderly dialysis cohort during the study 
period (214 primary and 84 secondary procedures). Only nine patients developed steal 
syndrome; in eight this required either ligation of their fistula or a revision using distal 
inflow (RUDI) procedure [88,89]. One further patient described marked hand 
claudication, associated with a systolic digital blood pressure of 54mmHg – this was 
treated conservatively. In agreement with published literature [73,74], steal syndrome 
developed much less frequently following formation of a wrist, than elbow, fistula (5 of 
51 (9.8%) for antecubital (BC and BB) fistulae and 4 of 247 (1.6%) for RC fistulae; P = 
0.009, Fisher’s exact test, Odds ratio 6.60). 
 
An additional consideration influencing the decision to site an AV fistula more 
proximally is the anticipated improved immediate patency rates in a dialysis population 
with limited life expectancy. Only 3 patients from our study population received a 
transplant. For the rest of the study population, in keeping with recent UK Renal 
Association data [155], survival was perhaps better than anticipated (Figure 4.5); at 
commencement of dialysis, of the patients aged 70 to 80, and those over 80 years, 53.9% 
and 46.3%, respectively, were alive four years later. 
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Figure 4.5: Kaplan-Meier analysis for patient survival according to age from 
commencement of dialysis 
As expected, survival outcomes were statistically significant between these 2 groups 
(P = 0.035, Log-rank test)  
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4.4 Limitations 
This was a single-centre retrospective cohort study examining access outcomes. The 
cohort examined was predominantly Caucasian.  As such, the sample population might 
not be entirely representative of the UK population at large. Furthermore, as a 
retrospective study, it come with all the limitations this this connotes.  
 
4.5 Discussion 
The best choice of permanent access procedure for elderly haemodialysis patients remains 
controversial [45,117,134,141,142]. Selection is based upon a number of competing 
factors such as: patient life expectancy; expected immediate patency rates; and risk of 
complications [141,156,157]. In this study, one of the largest series to date reporting 
outcomes for haemodialysis patients over the age of 70, we highlight that successful 
access placement can be achieved using an approach predominantly focused upon 
creation of RC fistulae. Creation of wrist fistulae in the elderly is not a novel concept, but 
perhaps the most important aspect of our study is that approximately 70% of our elderly 
patients successfully dialyse via a RC fistula. This represents a much higher proportion 
than reported in other publications detailing outcomes for elderly haemodialysis patients 
[156,158] and indeed, is higher than is typically reported by centres for their entire 
haemodialysis population [153,159,160].  
 
Nationally, unadjusted 4-year survival for incident haemodialysis patients aged ≥65 as 
reported in 2012 was 40.9% [155], and historically the median survival for very elderly 
patients (>75 years) is less than 2 years from initiation of dialysis.  In comparison, our 
elderly haemodialysis cohort aged ≥70 had a better than predicted survival, with 51.2% 
alive at 4 years. Thus, survival of the elderly dialysis population appears to be improving, 
suggesting that greater emphasis should be placed on conserving proximal access sites 
for future access provision. 
 
Our results suggest that for elderly patients with wrist cephalic veins greater than 2.5mm, 
creation of a radiocephalic fistula should be the first option assuming suitable arterial 
inflow. Such an approach would be anticipated to achieve reasonable patency rates and 
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to be associated with minimal complications, and in particular to carry a low risk for 
development of steal syndrome. This strategy moreover, provides the additional 
advantage of successful salvage and preservation of venous capital; it is notable in our 
series that the formation of a neo-vascular anastomosis improved 1 year patency rates by 
12%.  
 
The most appropriate choice for fistula placement in those patients with small cephalic 
veins (<2.5mm) who are nevertheless felt to have reasonable vein quality is more 
contentious. The immediate failure and primary patency rates for wrist fistulae created in 
these conditions were undoubtedly poor, with less than half achieving primary patency at 
one year. Nevertheless, secondary patency rates were acceptable and substantially better 
than the secondary patency rates for elbow fistulae created. It should however be 
emphasised that very few antecubital fistulae were performed as a primary procedure, 
and direct comparison between outcomes for elbow and wrist is therefore difficult, 
Moreover those patients in our study selected for brachiocephalic fistula as the first option 
for haemodialysis provision were generally considered to have poor quality radial artery 
or cephalic vein at the wrist and are perhaps a cohort selected to have inherently poor 
results for haemodialysis access provision. Nevertheless, it is undoubtedly more difficult 
to surgically salvage failed brachiocephalic than radiocephalic fistulae [146], which may 
partly explain why one year secondary patency rates were relatively poor for BC fistulae, 
despite the immediate patency rates being similar to those achieved for RC fistula. We 
do not routinely attempt radiological salvage of a failed BC fistula, because our 
experience mirrors reports from other centres  [50,161–163], in that improvements in 
fistula patency are only achieved by intensive and repeated radiological intervention.  
 
Accepting the above limitations with the analysis of outcomes for brachiocephalic fistula 
in our study, our findings, at the very least, raise questions as to the merits of an approach 
in elderly patients centred predominantly upon creation of elbow fistulae. Indeed, it 
would be difficult, given the high incidence of steal associated with elbow fistulae in our 
series, to justify such a change in our practice without performing a prospective trial in 
which elderly patients with small (<2.5mm) wrist cephalic veins that are deemed 
clinically usable are randomised to either radiocephalic or brachiocephalic fistulae. End 
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points would include: immediate failure rates; one and two-year patency; and 
development of clinically relevant steal.  
 
Finally, it is surprising that formation of proximal neo-anastomosis was reasonably 
successful in salvaging wrist fistulae which failed to mature, supporting the contention 
that the radial artery and cephalic vein at the wrist were of sufficient quality to attempt 
radiocephalic fistula creation, but that there are perhaps stochastic events that influence 
successful maturation. The neo-anastomosis was routinely performed just proximal to the 
initial anastomosis and it is therefore unlikely that the arterial and venous calibre differed 
significantly at the second anastomotic site. We are however careful to counsel patients 
regarding the relatively high risk of primary failure and that a secondary procedure may 
be required.  
 
4.5.1 Novel Findings 
In this chapter, I have demonstrated that: 
Successful radiocephalic fistula placement can be achieved in an elderly population and 
in our cohort approximately 70% dialyse via this modality. As outlined above, this 
represents a much higher proportion than in other publications outlining dialysis 
outcomes  for their elderly population. 
I also show that, for our cohort, four-year survival is better than expected. This could 
either reflect the generally higher socioeconomic status of the catchment area and 
consequently better health than the national average, or suggest that survival of the elderly 
dialysis population is improving. This improved survival suggests that, at least for our 
cohort, a greater emphasis should be placed on conserving proximal access sites for future 
access provision. 
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5 CONCLUSIONS 
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5.1 Conclusions 
Over the past decade, there has been an incremental growth of patients with end-stage 
renal failure on chronic haemodialysis. It is estimated that 10% of the population 
worldwide is affected by chronic kidney disease; over 2 million people worldwide 
currently receive treatment via dialysis or transplant, and this may only represent 10% of 
the actual population requiring renal replacement therapy [135,136].  Costs and 
complications have become increasingly significant components in the management of 
these patients. Ensuring functional vascular access is of paramount importance to not only 
the patient, but also to healthcare staff and the haemodialysis unit. An optimal access is 
one which provides long term patency, delivering adequate blood flow for efficient 
haemodialysis without associated complications. A structured surveillance programme 
allows for early identification of a failing access, allowing for prompt intervention and 
thereby increasing the overall lifespan of the vascular access. Similarly, prospective 
monitoring of an arteriovenous fistula could provide early detection of steal phenomena 
and allow for possible early intervention, thereby possibly preventing debilitating rest 
pain and tissue loss. 
 
Current guidelines published by the NKF-KDOQI, UK Renal Association and European 
Society for Vascular Surgery recommend that upper limb distal autogenous fistulae 
(RCF) should be created in the first instance, followed by more proximal fistulae 
(BCF/BBF)  [20–22]. Should this not be possible, a prosthetic graft or tunnelled CVC 
should be considered. Some authors have suggested that a blanket “fistula first” approach 
to access creation in the elderly may be detrimental given the time taken for an 
autogenous fistula to reach maturity, in addition to the multiple comorbidities and high 
patient mortality in this group [148,164,165]. Whilst this aspect might be true, it only 
highlights the importance of ensuring that a functional fistula is in place prior to being 
required. Guidelines advise early referral at least 3-6 months prior to the anticipated 
commencement of haemodialysis, allowing for AVF creation and subsequent maturation, 
as well as possible interventions to aid in the maturation process. Late referral for AVF 
creation risks potential non-maturation, being unsuitable for initiating haemodialysis, and 
need for CVC or prosthetic graft placement. Both CVCs and grafts have higher rates of 
infection. What is also true is that prosthetic grafts have a higher reintervention rate to 
maintain functional patency, and this also has an impact on the patient’s quality of life 
[148]. 
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The importance of “getting it right from the start” is critical. Initial decisions about 
vascular access modality have long term ramifications for patients and implications as to 
their time spent on dialysis. In recent years, there has been a drive towards a tailored 
“patient-centred approach” [123,141,166], with a reframing of the “fistula first” ideal to 
that of the “catheter last” [106,167]. To achieve this, proposed strategies include early 
identification of patients requiring vascular access, tailored fistulae taking into account 
expected patient life expectancy and potential failure rate [168,169], as well as 
implantation of early cannulation grafts [170,171]. Patients initiating dialysis via a central 
venous line are more likely to continue dialysing via line. Data from the UK renal registry 
indicate that 60% of patients starting on a tunnelled line continue to dialyse via line at 3 
months and >40% still dialyse via this modality at 1 year [65]. In this respect, 
Addenbrookes continues to be one of the leading centres in the UK where at 3 months 
from commencement of dialysis, almost half (48.6%) of all patients dialyse via AVF, 
with the national average being 27.7% [65].   
 
The focus of this thesis has been the examination of the manifestation of steal phenomena 
and steal syndrome in patients with autogenous arteriovenous fistulae. Within this thesis 
three themes have been explored: 
1. Digital finger pressures and its correlation to steal phenomena and steal syndrome 
2. Reduction of steal symptoms by means of utilising a distal arterial inflow 
3. Elderly patients initiating dialysis should still be considered for formation of a 
distal radiocephalic fistula  
 
Chapter 2 details the role that digital pressure has in identifying patients at risk of 
developing arteriovenous access ischaemic steal. Specifically, I demonstrate that patients 
with low brachial pressures tended to have corresponding lower digital pressures and 
were more symptomatic. This relationship has not been previously recognised in the 
literature. My data suggests that for individuals who experience debilitating steal, 
formation of an identical fistula on the contralateral side was just as likely to result in 
steal and should not be pursued, as the distal vasculature was likely to be comparable. I 
also establish that DP and DBPI can be used as a sensitive measure for detecting and 
predicting steal syndrome, with a DP of <65mmHg or DBPI <0.57 as the optimal point 
at which a patient is likely to have a positive clinical examination for steal. Further non-
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invasive testing with digital pressure measurements and derivation of the digital brachial 
pressure index may help in the diagnosis and decision-making process. This has particular 
relevance in satellite or rural haemodialysis units where there is limited clinician 
availability and would serve as a quantitative means for non-clinical staff to identify 
patients at risk of developing steal.  
 
In our cohort, 28.3% of patients had at least one clinical sign of steal syndrome, which 
was not anticipated, given that current published literature suggests that the incidence of 
steal is approximately 5% [71]. This implies that the incidence of mild steal symptoms is 
under-reported, or perhaps under-appreciated. Whilst this represents a significant 
proportion of our cohort, none of these individuals experiencing AVAIS required surgical 
intervention.  
 
I established that there was poor linear correlation between the Steal symptom score 
proposed by van Hoek et al [110] and DP / DBPI. Disappointingly, it did not offer a 
means to stratify symptom severity, making it difficult to draw any meaningful 
conclusions when comparing patients with varying Steal symptom scores. Instead, the 
classification system proposed by Tordoir and Scheltinga [71,75] proved to be more 
valuable for making comparisons. We recommend that this grading system should be 
used in clinical practice and when reporting outcomes.  
 
Chapter 3 outlines the results of an ongoing single-blinded randomised trial comparing 
the incidence of steal symptoms in antecubital fossa fistulae utilising different arterial 
inflows. We report the incidence of steal according to grade of severity and demonstrated 
that patients receiving haemodialysis via antecubital fossa fistulae experience a greater 
incidence of steal phenomena (66%) than has previously been reported in the literature. 
This result was significantly greater than the proportion (28.3%) exhibited in Chapter 2, 
which examines patients dialysing via all autogenous fistula modalities. In our cohort, 
30% had moderate to severe symptoms, which is greater than what has been previously 
reported. The proportion of patients with moderate to severe symptoms which then 
progress to require surgical intervention remains uncertain, and would be the basis for 
further longitudinal studies.  
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Regardless of intervention performed, a lower pre-operative DP / DBPI was likely to give 
rise to more severe grades of steal. This relationship is not widely appreciated in the 
current vascular access literature. Greater dissemination of this association would help 
clinicians ascertain each individual’s potential risks of steal syndrome and inform the 
consent process. We thus recommend that all patients undergoing autogenous fistula 
creation, and in particular patients receiving an antecubital fossa fistula, should have their 
preoperative DP and DBPI measured.  
 
Patients who received Intervention B (proximal radial/ ulnar artery inflow) demonstrated 
significantly less incidence of severe steal, and less steal symptomatology overall. We 
demonstrated that both interventions had comparable 6-month fistula survival and that 
there was no difference in 6-month fistula outcomes (functional, thrombosed, failure to 
mature and other). Given the above, our findings are compelling and certainly has 
effected a change in our clinical practice, where patients with multiple risk factors for 
steal (diabetes, hypertension, ischaemic heart disease) have a PRCAVF / PUCAVF 
created in preference to a BCF. Nevertheless, we also established that severe digital 
ischaemia due to steal which required intervention was a rare entity, with only one patient 
in our cohort requiring surgery. Given the above findings, our recommendation is to 
consider formation of a PRCAVF / PUCAVF in preference to a BCF, particularly if risk 
factors for steal and low finger pressures are present. 
 
Examination of the total Steal symptom score at 6 months did not reveal a significant 
difference in both interventions; this also held true when examining the individual 
parameters which comprise the score. As discussed above and in Section 3.12, this is 
perhaps due to each component being given equal weightage when in fact they represent 
progression of ischaemic symptoms. No linear correlation between score and symptoms 
was found, and therefore the score has limited clinical value and should not be used in 
routine clinical practice. 
 
Identifying patients which required placement of an antecubital fossa fistula proved to be 
challenging. This was primarily due to the successful implementation of our 
radiocephalic fistula programme, which created functional radiocephalic fistulae which 
could sustain dialysis. In effect, we were a victim of our own success. The protracted 
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patient recruitment process necessitated several extensions to the projected trial end date. 
This recruitment obstacle led to the exploration detailed in Chapter 4, which challenges 
the notion that elderly patients should have proximal fistulae sited routinely.  
 
Moving forward, valuable lessons were learnt in the inception, organisation and 
administration of this randomised controlled trial. We should have identified that the 
lengthy study duration would be a significant issue and taken steps to address this. The 
length of study and funding issues precluded the recruitment of a singular trial 
coordinator, which would have been invaluable. An alternative solution would have been 
enlisting the help of other centres, which would have necessitated amendments to the 
ethical approval, “buy-in” from the other centres, more staff and appropriate funding to 
be in place. These are important lessons which can be applied to further trials. 
 
In Chapter 4, I report the outcomes for elderly incident haemodialysis patients at our 
institution utilising a retrospective analysis, highlighting that successful dialysis access 
can be achieved despite employing a strategy with favours radiocephalic fistula 
placement. This is in contrast to the current accepted dogma that elderly patients should 
have proximal (antecubital fossa) fistulae created in order to reduce the risks of non-
maturation. My results show that approximately 70% of our elderly cohort dialysed 
successfully via RCF, which represents a higher proportion than reported in other 
publications and other centres for their entire haemodialysis population. The results also 
suggest that as long as the distal cephalic veins are larger than 2.5mm, reasonable patency 
rates are achievable for RCFs given suitable arterial inflow. This is in agreement with a 
systematic review examining cephalic vein and radial artery diameter in RCF formation, 
which suggests that the minimum radial artery and cephalic vein diameter is 1.5mm and 
2.0mm respectively [172]. Below this threshold, maturation and primary patency rates of 
RCFs are poor. We also demonstrated that complication rates, including the dreaded steal 
syndrome, for distal fistulae are exceedingly low. 
 
In contrast to other authors, our results suggest that patient age should not factor into 
vascular access strategy [120,139,141,148,173]; rather, projected life expectancy should 
be the measured variable instead. Our results in Chapter 4 demonstrate that for patients 
over the age of 80 initiating haemodialysis, 46.3% were alive four years later. Advanced 
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age is merely used as a surrogate for diminished life expectancy and multiple 
comorbidities. Projected life expectancy is understandably a nebulous concept that is 
difficult to quantify and reach agreement on, but nonetheless this is an important 
distinction to make. Given our results, we suggest that in elderly patients with anticipated 
longer life expectancies, a greater emphasis should be placed on conserving proximal 
access sites in preparation for future access provision. For individuals with an anticipated 
short life expectancy an autogenous fistula might not be the ideal choice for vascular 
access and indeed there should be a discussion of whether initiation of haemodialysis 
would improve the patient’s quality of life or extend life expectancy significantly. 
 
Given the chronic nature of renal failure, patients are unlikely to have a single form of 
vascular access, and over the course of their life receive renal replacement via a 
combination of fistulae, catheters, grafts, peritoneal dialysis and/or renal transplants. The 
most suitable access for a patient remains one that integrates individual circumstances 
and projected haemodialysis duration, whilst also considering patient comfort, 
satisfaction, quality of life and clinical outcomes. Patients should receive uninterrupted 
use of the access with minimal need for intervention and this would allow for the 
prescribed dialysis regimen to be received with minimal disruption. We have 
demonstrated that at our institution, we are able to create successful autogenous AV 
fistula in the majority of our patients, delivering effective haemodialysis.  
 
Each access surgeon’s training, skill, experience and outcomes will be different. Fistula 
outcomes are also dependent on institutional factors such as the availability of a vascular 
scientist, interventional radiology support as well as dialysis centre expertise. Our results 
show that establishing and maintaining autogenous access is attainable for most patients 
and should be vigorously pursued. In addition, understanding surgeons’ preferences, 
values and beliefs around AVF eligibility is important to explain variability in practice 
[123]. Significant variability remains in surgical preoperative assessments and the 
eligibility criteria used for fistula creation. In a survey of vascular access surgeons 
performed by Nica et al [123], absolute contraindications to AVF creation included life 
expectancy of <1 year, left ventricular ejection fraction of <15% and pre-existing 
dementia.  Increased comorbidities, small vessel diameter and previous failed access were 
deterrents to AVF creation.  
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5.2 Future trends in haemodialysis 
Determining the optimal time to create an arteriovenous fistula or factors which can 
predict the progression to ESRF remains a challenge [156,174]. No current clinical 
practice guideline exists to drive rapid placement of definitive access amongst late 
presenting individuals; responsive dialysis access pathways involving prompt assessment 
by a nephrologist and rapid referral to a dialysis access surgeon should be prioritised. 
There remains considerable UK wide variation in access modality provision despite 
adequate infrastructure in place to support delivery of quality vascular access [175]. 
 
The rate of renal function deterioration appears to be an important factor in determining 
the optimal time for AVF creation [176]. As the rate of renal function decline is 
unpredictable, early creation of an AVF might not necessarily be the optimal strategy for 
pre-dialysis patients with a slow rate of renal deterioration, and a better understanding of 
the factors involved and better risk models are required [139]. It has also been suggested 
that very early AVF creation in the elderly cohort might expose patients to unnecessary 
operations and interventions in the event of death prior to requiring haemodialysis 
[141,176]. To that end, the kidney failure risk equations proposed by Inston et al  [177] 
which estimates the probability of the 2- and 5-year risk of reaching end stage kidney 
disease shows promise, but further validation studies are required. Future studies 
evaluating the timing, modality of vascular access, considering complications, 
functionality, as well as patient preference are required, in order that optimised care can 
be provided and quality of life maintained.  
 
What also remains to be addressed is the optimal access strategy for “crash landers” – 
patients who require immediate renal replacement upon presentation. For this cohort of 
patients requiring urgent dialysis, fistula placement often follows CVC line insertion. In 
this respect, early cannulation grafts certainly do show promise as an alternative to 
tunnelled CVCs for patients requiring urgent vascular access. Bacteraemia rates appear 
to be lower, and mortality rates are similarly superior  [61,62] 
 
Maturation times and fistula failure continue to present significant obstacles to successful 
fistula utilisation. Effective solutions require an appreciation of the modes and pathology 
of access failure which is still poorly understood [49,178]. A multidisciplinary approach 
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involving nephrologists, access surgeons and radiologists, coupled with appropriate 
patient selection and tailored treatments should improve patient outcomes [179]. 
 
5.3 Future research 
I intend to implement the findings garnered from this thesis and pursue further research 
in vascular access to ensure that patients receive the best quality of care available. With 
access to a vascular laboratory, preoperative arterial waveform analysis could be carried 
out, which can identify individuals in need for more detailed arterial duplex mapping or 
angiography, highlighting arterial stenoses which can be addressed prior to fistula 
formation. Determining the role of ultrasound surveillance of fistulae, its effectiveness in 
predicting fistula maturation and whether surveillance can extend secondary patency by 
early identification of a “failing fistula” are questions which still have not been 
definitively addressed in the literature [39,180]. Identifying patients at risk of non-
maturation, coupled with early assessment and prompt recognition of a failing or “failing 
to mature” fistula would allow for rapid intervention, ensuring continued dialysis via 
autogenous fistula [49]. Whether these interventions should involve open surgery or 
endovascular techniques would depend on each centre’s strengths and available facilities, 
and there needs to be clear guidance in this respect [181]. Whether pre-emptive 
intervention should be performed is also a matter of contention, with a  recent Cochrane 
review finding that it did not enhance access longevity, while possibly resulting in an 
increase in access-related procedures and consequently procedure related adverse events 
[182] .  
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Participant Information Sheet 
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and Steal Syndrome 
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We would like to invite you to take part in our research study. Before you decide we 
would like you to understand the purpose of this study and what it would involve if you 
participate. One of our research team will go through the information sheet with you and 
answer any questions you have.  
 
Part 1: Background of Study 
1.1  What is arteriovenous fistula? 
An artery is a blood vessel through which blood flows from the heart to the rest of the 
body. A vein is a blood vessel through which blood collected from different parts of the 
body returns to the heart.  
An arteriovenous fistula (AVF) is a connection between an artery and a vein. An AVF 
for haemodialysis is surgically created by joining the vein to the artery. This allows the 
vein to grow larger and stronger and provides easy access to the blood stream during 
dialysis.  
 
1.2 Are there different types of AVF? 
Yes. AVFs can be classified by the sites where they are created. They are mostly created 
on the arm but in rare cases they can be formed on the leg or ankle. In this study, we will 
look at elbow fistulae.  
 
1.3 Why do you need an elbow fistula? 
The strategies in creating AVFs for dialysis is to start in an area furthest from the trunk 
and if that fails, to form it closer to the trunk. For example, in the arm, the preferable site 
for AVF is the wrist, followed by the middle part of the forearm and then the elbow. 
In case of no suitable vessels available for AVF creation in the wrist or forearm, either 
because the vessels are too small or contain clots, we will create an elbow fistula. 
 
1.4 What are the risks of having an AVF? What is Steal Syndrome? 
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As in any other surgical procedure, creation of AVF can be complicated by bleeding and 
infection. Bleeding can occur immediately after the operation or can be prolonged after 
needling during dialysis. If infection occurs, most of the time it can be treated with 
antibiotics but in some cases it can lead to loss of the AVF.  
Other risks include clot forming within the AVF, narrowing of the vessels close to the 
AVF and failure of the vein to expand. All of these can cause failure of the AVF.  
Steal syndrome is another complication that can occur following AVF creation. It is 
caused by the decreased blood supply to the hand because blood is 'stolen' from the artery 
to the vein. It can cause a cold and pale hand, numbness, pain and, if left untreated, it can 
cause death of tissue in the hand ranging from ulcers to loss of fingers in severe cases. It 
is therefore important to recognise symptoms of steal early. There are different treatments 
for steal syndrome; in severe cases the fistula is tied off.  
1.5 Who is at risk of getting steal syndrome? 
All patients with AVFs are at risk of developing steal syndrome. Studies have shown that 
people with diabetes are at higher risk of getting steal. It has also been found that Steal 
occurs more frequently in elbow fistulae than in mid-forearm or wrist fistulae.  
 
1.6 Why does an elbow fistula have a higher risk of steal syndrome? 
An elbow fistula is usually created using the main artery called the brachial artery. This 
artery divides into two smaller arteries named the radial artery and the ulnar artery. It is 
believed that an AVF using the brachial artery can potentially disturb the blood flow in 
both the radial and ulnar arteries, whereas an AVF below the elbow only involves one of 
the two arteries, therefore the blood supply to the hand is less likely to be disturbed in a 
wrist or mid-forearm fistula.  
On the basis of this theory, some surgeons have suggested that using either the radial or 
ulnar artery instead of the brachial artery can reduce the risk of steal syndrome in elbow 
fistulae. In this study, we aim to find the clinical evidence to support this theory. 
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Part 2: Purpose of Study and Study Procedure 
2.1 What is the purpose of the study? 
The purpose of the study is to compare the two surgical methods in creation of an elbow 
fistula using either the brachial artery or one of its two branches - the radial or ulnar artery. 
The aim of our study is to find out if the latter method has a lower risk of causing Steal 
Syndrome. The result of this study will help future surgeons decide which method they 
can use to reduce the risk of steal syndrome.  
 
2.2 Why have I been invited? 
You are invited to take part in this study because you are going to have an elbow fistula. 
An elbow fistula is considered to be the best option for you because there is no suitable 
vessel in your wrist or forearm for creation of an AVF.  
 
2.3  Do I have to take part? 
It is up to you to decide whether to take part in the study. We will explain to you what the 
study will involve, its risks and benefits and will go through this information sheet with 
you before you make a decision. If you decide to take part, we will then ask you to sign 
a consent form. You are free to withdraw at any time, without giving a reason. This would 
not affect the standard of care you receive.   
 
2.4 What will happen to me if I take part? 
Your participation in this study will be approximately 7 months from the time you are 
approached by the investigator.  
This is blinded randomised trial. A randomised trial means that you will be allocated to 
one of the study interventions by chance (randomly). We don't know which of the two 
study interventions is better for patients. We therefore put patients into two groups 
randomly and each group undergoes one intervention. The results are compared to see 
which one is better. You will be 'blinded' i.e. you will not be told which intervention 
group you are in.  
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Once you are identified as a potential participant for the trial, you will be approached by 
the investigator either when you are in the clinic, or in the ward if you have been admitted, 
or by phone. The investigator will explain to you briefly about the trial. If you are 
interested in taking part, you will then undergo the following Trial Procedures.  
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Post-intervention Assessment (Week 3, 12 & 24)
This will be carried out by the investigator. The paricipant will be asked to score any 
steal symptoms and examined for sign of steal and other complications. Blood pressure 
measurement and USS will be performed by the investigator. 
Post-intervention Phone Interview (Week 1)
The participant will be phoned by the investigator at 1 week. He/she will be asked 
to score any steal symptoms. In case of severe symptoms, he/she will be brought to 
clinic for examination.  
Intervention
The vascular access waiting list  coordinator will reveal the randomised 
intervention from the pre-sealed envelope and inform the operativng surgeon 
which intervention to perform:
Intervention A: Brachial artery AFF or Intervention B: Proximal radial/ulnar artery AFF 
Pre-intervention Assessment
This will be done by the investigator in vascular access clinic, ward or dialysis unit. 
Relevant medical history will be obtained. Physical examination, blood pressure 
measurement and ultrasound scan of the upper limb will be carried out by the 
investigator. 
Consent and Randomisation
Patients who are willing to take part in the trial will be asked to sign a consent form. The 
participant will then be given a Participant ID Number. All trial data will be recorded 
under this number. The Participant ID No. is linked to a numbered envelope pre-sealed 
with a randomised trial intervention. 
Referral to STEAL Trial & Pre-trial 
consultation
Patients who have fulfilled the STEAL Trial inclusion criteria will be invited to meet 
the investigator when the trial procedure, risks and benefit will be explained to 
them.   
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2.5  Expenses and payments 
Travel expenses will be available when you make a trip to Addenbrooke's Hospital for 
the pre-intervention assessment and follow-up assessments. If you require hospital 
transport, we will arrange that for you. If you use your own transport, please keep your 
receipts or let us know the distance you have travelled, so that we can help you to claim 
your travel expenses.  
 
2.6 What will I have to do? 
You will need to attend all the scheduled pre-trial interviews and assessment, the trial 
intervention and follow-up assessments as described in Section 2.4.  
 
2.7 What are the possible disadvantages and risks of taking part? 
The risks of taking part in this study are no different from the risks associated with any 
fistula creation. Please refer to Section 1.4 to 1.6 for the risks of elbow fistula. If you are 
randomised to undergo Intervention B (proximal radio/ulnar artery AVF), the operation 
will take approximately 10 to 15 minutes longer than Intervention A (brachial artery 
AVF). The risk of getting minor complications such as bleeding, infection and clots has 
no difference between the two study interventions.  
Based on the clinical assessments by your nephrologist and the transplant surgeon, it has 
already been decided that an elbow fistula is the most appropriate means for you to have 
haemodialysis. The two surgical methods involved in this trial are both regularly used in 
creation of elbow fistulae. You would undergo one of these two procedures even if you 
were not involved in this study. The only difference is that the decision of which 
procedure you will undergo will be made by the trial randomisation process if you take 
part. This would otherwise be decided by the operating surgeon according to the 
individual surgeon's preference and assessment.  
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2.8  Radiation and the Ionising Radiation (Medical Exposure) Regulations (IRMER) 
You will have a series of ultrasound scans to assess the blood vessels in your arms 
throughout this study. This does not involve any radiation or ionising radiation.  
 
2.9 What are the possible benefits of taking part? 
We will follow you up more closely after your AVF creation. Patients who have had AVF 
creation would generally be seen at Vascular Access Clinic once after the procedure or 
be followed up at their routine Nephrology Clinic. As a trial participant, you will be 
followed up by the investigator at 1 week (by phone), 3 weeks, 3 months and 6 months 
after the procedure. The investigator will pay special attention to any complications that 
could arise so they can be treated as early as possible.  
 
2.10 What happens when the research study stops? 
At the end of your participation, we will notify your nephrologist in writing so that you 
will continue your follow up at your local Nephrology Clinic or Dialysis Unit.  
You will receive a report on the study results and will be told which study group you have 
been in at the end of study. We estimate that it will take 3 years to complete this study.   
 
2.11 What if there is a problem? 
Any complaint about the way you have been dealt with during the study or any possible 
harm you might suffer will be addressed. The detailed information on this is given in Part 
3.  
 
2.12 Will my taking part in the study be kept confidential? 
Yes. We will follow ethical and legal practice and all information about you will be 
handled in confidence. The details are included in Part 3.  
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Part 3 Study Information, Medico-Legal and Ethical Issues 
3.1 What if relevant new information becomes available? 
Sometimes we get new information about the treatment being studied. If this happens, the 
investigator will tell you and discuss whether you should continue in the study. If you 
decide to not to carry on, the investigator will make arrangements for your care to 
continue. If you decide to continue in the study, you will be asked to sign an agreement 
outlining the discussion.  
 
3.2 What happens if I don't want to carry on with the study? 
You may withdraw at any stage of the study, either before or after the study intervention. 
If you withdraw after you have had the study intervention, information collected up to the 
point of your withdrawal may still be used for study analysis.  
 
3.3 What if there is a problem? 
Complaints 
If you have a concern about any aspect of this study, you should ask to speak to the 
investigators who will do their best to answer your questions (You will find the contact 
details of the investigators at the end of this information sheet). If you remain unhappy 
and wish to complain formally, you can do this via the NHS Complaints Procedure.  
 
Harm 
In the event that something goes wrong and you are harmed during the research, and this 
is due to someone's negligence, then you may have grounds for a legal action for 
compensation against Cambridge University Hospitals NHS Foundation Trust, but you 
may have to pay your legal costs. The normal National Health Service complaints 
mechanisms will still be available to you.  
 
3.4 Will my taking part in this study be kept confidential?  
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All information which is collected about you during the course of the research will be 
kept strictly confidential. 
Once you take part in this study, you will be given a Participant ID Number. All the data 
we collect from you will be recorded and stored under this number. Only authorised 
persons (i.e. investigators, trial staffs and Research & Development personnel who are 
responsible for monitoring of quality of the study) will have the access to view 
identifiable data.  
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3.5 Involvement of the General Practitioner (GP) 
It is not necessary to notify your GP about your participation in the study. A discharge 
letter will be sent to your GP as a routine procedure after your operation but this is not 
part of the study procedure.  
 
3.6 What will happen to the results of the research study? 
We intend to publish the results of this study in scientific journals. We will send you a 
report of the study once the results are available. You will not be identified in any report 
or publication.  
 
3.7  Who is organising and funding the research study? 
The study is organised and conducted by the Department of Surgery, Cambridge 
University Hospitals NHS Foundation Trust.  
The study is funded by NIHR Cambridge Biomedical Research Centre, Transplant Theme.  
The investigators will not be paid for conducting the study. There is no conflict of 
interests.  
 
3.8 Who has reviewed the study? 
All research in the NHS is looked at by independent groups of people, called the Research 
Ethics Committees, to protect your interests. This study has been reviewed and given 
favourable opinion by Cambridgeshire 2 Research Ethics Committee.  
 
3.9 Further information and contact details 
For general information about research, please visit the Cambridge University Hospitals 
NHS Foundation Trust Research & Development website: 
http://www.cuh.org.uk/research/public/public_index.html 
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OR contact: 
Patient Advice & Liaison Service (PALS)  
Cambridge University Hospitals NHS Foundation Trust 
Tel:  01223 216756 
Email:  pals@addenbrookes.nhs.uk 
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For specific information about this research study and advice as to whether you should 
participate, please contact one of the investigators: 
1.  Mr Gavin Pettigrew (Chief Investigator) 
 Honorary Consultant Surgeon & Lecturer 
 Department of Surgery 
 Box 202, Level E9 
 Cambridge University Hospitals NHS Foundation Trust 
 Hills Road 
 Cambridge 
 CB2 0QQ 
 Email:  gjp25@cam.ac.uk 
 Contact number:  01223 762523 
 
2.  Mr Aaron Goh (Investigator) 
 Clinical Research Fellow 
 Department of Surgery 
 Box 202, Level E9 
 Cambridge University Hospitals NHS Foundation Trust 
 Hills Road 
 Cambridge 
 CB2 0QQ 
 Email:   aaron.goh@addenbrookes.nhs.uk 
 Contact number:  01223 336975 
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If you are unhappy with the study, please contact one of the investigators or you could 
make a formal complaint via NHS Complaints Procedure. You could find this 
information in the following website: 
http://www.nhs.uk/choiceintheNHS/Rightsandpledges/complaints/Pages/NHScomplaint
s.aspx 
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7.4 Pre-intervention assessment form (steal trial) 
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7.5 Trial-specific operation record (steal trial) 
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7.6 Post-intervention assessment form (steal trial) 
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